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ABSTRACT 
 
Liver transplantation (LT) is the treatment of choice for patients with severe liver 
disease.  Quality of life of patients after LT may be comparable to that of the general 
population, but permanent immunosuppression poses a high risk for infections. Highly 
prevalent dental diseases not promptly treated may compromise LT outcome.  All possible 
infectious foci, including dental infections, should thus be treated prior to LT.  This thesis 
aimed to investigate how liver diseases and long-term immunosuppression after LT affect 
oral health and whether dental infections are associated with liver disease progression or with 
LT outcome. 
 
The study design was retrospective, cross-sectional, and observational.  The study comprised 
263 adult recipients of a LT between 2000 and 2006 at the Helsinki University Central 
Hospital, Finland.   Of these patients, 212 (81%) had chronic liver disease, and all underwent 
dental examinations and treatment prior to LT.  The study investigated the effect of differing 
liver disease etiology and severity on oral health status; the effect of dental infections on the 
progression of liver cirrhosis was further studied in a subgroup of 116 cirrhotic patients 
awaiting  LT.   
 
Of the study patients, 51 (19%) had acute or subacute liver failure; these were further 
stratified by whether or not they received pretransplant dental treatment. Post-transplant 
systemic infectious complications were evaluated from the Finnish Liver Transplant Registry. 
 
After a minimum 2-year follow-up (median follow-up 6 years, range 2-11), all 84 eligible LT 
recipients were recruited for a new oral health examination according to a fixed protocol.  A 
structured questionnaire was used to assess dry-mouth-related symptoms, with oral Candida 
cultivated, and salivary flow rates measured.  The results were compared with those of 252 
matched controls from a national health survey.  Subjects were grouped according to liver 
disease etiology and type of immunosuppression.   
 
Dental health status of LT candidates varied depending on the etiology and severity of their 
liver disease.  Alcohol cirrhosis patients (n=37) had significantly more tooth extractions 
before LT than did primary sclerosing cholangitis patients (n=54)  (6 vs. 3, P<0.005).  Poor 
liver function, as observed in higher Model for End-Stage Liver Disease (MELD) scores, 
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associated with fewer teeth (21 vs. 25, 95%CI: -6.7-(-)1.4, P<0.005) and more tooth 
extractions (5 vs. 2, 95%CI: 1.6-4.2, P<0.001).  Tooth extractions were often associated with 
severe complications such as bleeding.  Several dental infections in cirrhotic patients 
associated with worsening of the liver disease as seen in the shorter time between diagnosis 
and LT operation.  Post-transplant infection risk, especially sepsis, was higher in those acute 
liver disease patients who received no dental treatment before LT due to their more urgent 
need for LT compared with that of patients who had received dental treatment (OR=8.54, 
95%CI: 1.82–40.1, P<0.05).  This risk was independent of age, gender, etiology of acute liver 
failure, waiting-list time, MELD score, or level of immunosuppression. 
 
Compared with controls, chronic LT recipients had significantly more caries (1.2 vs. 0.5, 
P<0.005) and a higher prevalence of dysphagia (23% vs. 12%, P<0.05).  They also had lower 
unstimulated salivary flow rates than did the acute LT recipients (0.3 ml/min vs. 0.6 ml/min, 
P<0.05).  Oral mucosal lesions were significantly more frequent in LT recipients than in 
controls (43% vs. 15%, P<0.001).  Drug-induced gingival overgrowth was the most common 
type of oral lesion, and its prevalence was significantly higher in chronic LT recipients than 
in their controls (16% vs. 1%, P<0.001).  Simultaneous use of cyclosporine-A and calcium- 
channel blockers increased the overgrowth prevalence even further compared with the 
tacrolimus group (47% vs. 8%, P<0.05).  Precancerous oral mucosal lesions occurred twice 
as often in chronic LT recipients as in controls (13% vs. 6%, Ns).  Oral Candida count was 
positive in more than half the LT patients; use of steroids raised its prevalence to 70%.  
 
The need for dental treatment hence was high before the LT operation with differences in oral 
health between groups differing in liver disease etiology and severity.  Among cirrhotic 
patients, several dental infections were reflected in the liver disease progression.  Those 
patients who lacked dental treatment before LT showed an 8-fold risk for systemic infections 
after transplantation.  Compared to controls, immunosuppressive and other xerogenic 
medications predisposed especially the chronic LT recipients to more dry-mouth-related 
symptoms and caries, and led to a higher risk for oral mucosal lesions, of which some were 
precancerous.  Thus, both pre- and post-transplant dental treatments are highly important for 
these patients.  
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ABBREVIATIONS         
 
ALF, acute liver failure  
BMS, burning mouth syndrome                          
CD, Crohn’s disease 
CI, confidence interval 
CLD, chronic liver disease 
CMV, cytomegalovirus 
CNI, calcineurin inhibitor 
CsA, cyclosporine-A 
DIGO, drug-induced gingival overgrowth 
EBV, Ebstein Barr virus 
HBV, hepatitis B virus 
HCC, hepatocellular carcinoma 
HCV, hepatitis C virus 
HPV, human papillomavirus 
HSV, herpes simplex virus 
HUCH, Helsinki University Central Hospital 
IBD, inflammatory bowel disease 
IL, interleukin 
INR, international normalized ratio 
LT, liver transplant(ation) 
MARS, Molecular Absorbent Recirculating System 
MELD, Model for End-Stage Liver Disease 
MMP, matrix metalloprotease 
mTOR, mammalian target of rapamycin 
Ns, not significant 
OLP, oral lichen planus 
OML, oral mucosal lesion 
PBC, primary biliary cirrhosis 
PSC, primary sclerosing cholangitis 
PTG, panoramic tomography 
SCC, stratified squamous cell carcinoma 
SBP, spontaneous bacterial peritonitis  
TAC, tacrolimus 
UC, ulcerative colitis 
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INTRODUCTION 
 
Chronic liver disease (CLD) is a growing problem worldwide due to an increased incidence 
of diabetes, obesity, and lifestyle habits but also for autoimmune causes.  Liver 
transplantation (LT) is a life-saving treatment for patients suffering from end-stage CLD that 
no longer is curable by conservative treatment.  Patients with acute liver failure (ALF) or 
liver tumor may also be the recipients of a LT.   
 
The first human LT in the world was performed by Thomas Starzle in 1963 in Denver, 
Colorado; he performed the first successful human LT later, in 1967.  The first European LT 
followed a year later by Sir Roy Calne in Cambridge, UK.  The first Scandinavian LT was at 
the Helsinki University Central Hospital (HUCH) in 1982.  Since then, the prognosis has 
steadily improved with current 5-year survival rates reaching close to 90%, and transplant 
recipients’ quality of life resembles that of the normal population (1).  Advances in successful 
outcomes are mainly due to modern immunosuppressive medication which these patients 
receive to prevent rejection of the transplanted graft.  Today, patient survival is so good, that 
the main focus in development of more potential immunosuppression has shifted towards 
reducing complications after LT. 
 
Permanent immunosuppression predisposes to infections which are the leading cause for 
mortality after LT (2,3).  The first post-transplant year is critical; more than half the LT 
recipients experience infectious complications early on, but the risk for infections remains 
throughout their lives.  To prevent post-transplant systemic infections, it is crucial that before 
the patient is placed on a waiting list for LT, all potential infection foci are treated (4,5).  
Among infections, sepsis is one of the most common.  An oral pathogen, Streptococcus 
viridans, has been identified as source of septic complication following LT (6), meaning that 
before LT, elimination of oral infectious foci is essential. 
  
Oral examination for any suspicious oral or dental infection foci has been routine since the 
start of the LT program in Finland.  Most worldwide transplant centers also recommend pre-
transplant dental evaluation to prevent bacteremia and sepsis and eventually to improve LT 
recipients’ outcome (7-11).  Dental treatment of these immunocompromised patients is 
carried out in a hospital setting under antibiotic prophylaxis to prevent infection spread; 
blood transfusions are also available, if necessary, for bleeding (12). 
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Regular oral examinations are needed also after LT, since organ-transplant recipients are at 
risk for various orofacial diseases (13).  Risk for premalignant oral mucosal lesions is 
elevated, and therefore the lips and oral mucosal tissues need careful examination for possible 
neoplasias (14).  After LT, osteoporosis and osteopenia are quite common, and alveolar bone 
loss of the jaws can also occur (15,16). 
 
Studies in this field have not taken place before in Finland, and very few data exist regarding  
dental treatment of LT recipients.  Although empirical knowledge demands pre-transplant 
dental treatment, clinical recommendations vary greatly, for instance the extent of eradication 
of oral and dental infectious foci before organ transplantation, or the need for antibiotic 
prophylaxis in dental procedures afterwards (17,18).  Benefits from treatment of infected 
teeth in reducing septic infections in LT recipients, have been poorly studied. 
 
This thesis focused on the issue of oral infections before and after LT and the systemic 
infections that oral infections may trigger, while in other fields of medicine the effect of oral 
infections has been well established in this regard (19,20).  Since LT may be done for various 
reasons, differences in oral health may exist between different etiology- or 
immunosuppressant groups and may also depend upon the severity of the liver disease.  
Although liver cirrhosis as such has been well studied, the effect of dental infections on the 
progression of CLD deserved study in more detail.  The main emphasis in this series of 
studies was to investigate the possible benefits of dental treatment on the outcome of LT and 
the importance of pre- and post-transplant dental care for the well-being of these patients. 
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LITERATURE REVIEW 
 
Liver 
 
Anatomy and function of the normal liver 
 
The liver is the largest internal organ and also the largest gland in the human body, weighing 
about 1.5 kg.  No human being can survive without a liver, which can be seen as a large filter 
or the biochemical factory of the body.  It is situated in the right upper abdominal cavity, 
protected by the rib cage, divided into segments (Fig. 1).  It has a dual blood supply; the 
hepatic artery brings fresh, oxygenated blood from the heart, while the portal vein supplies 
blood from the intestines and spleen.  The liver receives 75% of its blood from the portal vein 
and the rest from the hepatic artery.  Both hepatic artery and portal vein enter the liver at the 
hilus, along with afferent nerve fibers. 
 
The main cell types are the hepatocytes which are responsible for most functions of this vital 
organ (21).  The functional unit of the liver is the acinus, which is microscopic in size and has 
a berry-like structure (Fig. 2).  Oxygen tension and nutrient level decrease from zone 1 
towards zones 2 and 3.  Zone 1 hepatic cells are the first to receive oxygenated blood and the 
last to go into necrosis, in comparison to zone 3, where perfusion is lowest, making this area 
therefore the most severely affected.  The lobule is the histologic unit of the liver with a 
hexagonal structure.  This vascular structure includes a network of sinusoids with a central 
area that contains the hepatic vein.  The outer corners contain the portal triads: hepatic artery, 
portal vein and the bile duct. 
 
Being part of the gastrointestinal system, the main task of the liver is to help in digestion.  
The portal vein brings digested food particles to the liver, which then processes and delivers 
to the inferior vena cava, via the hepatic vein, all the nutrients that the body needs for energy.  
The liver produces bile that is transported via bile ducts for storage in the nearby gallbladder.  
To aid in lipid metabolism, this yellow-greenish substance is then secreted to the small 
intestine.  The liver synthesizes proteins (e.g. albumin), several hormones, and coagulation 
factors and is responsible for the metabolism of glucose and storage of several fat-soluble 
vitamins.  The liver detoxifies harmful substances such as alcohol, drugs, and bacterial toxins 
from the blood.  Other life-supporting functions include the liver’s ability to fight against 
infections by use of its macrophage Kuppfer cells. 
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The liver supports almost all organs.  Maintaining blood pressure via the renin-angiotensin 
mechanism is an example of interplay between the liver and the kidneys.  Severe liver failure 
may lead to multiorgan failure with often fatal consequences. 
 
Figure 1.  Liver sections and vascular anatomy.   
 
Source:  internet, open source (modified). 
 
 
 
Figure 2.  Acinus and lobule.   
 
 
 
 
Source:  with permission from the author (22). 
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Liver diseases 
 
Liver diseases can be classified by their etiology.  This classification includes chronic liver 
diseases (CLD), acute liver failure (ALF), and liver tumors.    
 
Table 1.  Liver diseases. 
 
 
Chronic liver diseases Cholestatic liver diseases Primary biliary cirrhosis (PBC)         
  Primary sclerosing cholangitis (PSC) 
 Cirrhotic liver diseases Alcohol cirrhosis 
  Autoimmune cirrhosis 
  Non-alcohol steatohepatitis (NASH) 
  Cryptogenic cirrhosis 
  Other cirrhosis  
 Metabolic Wilson’s disease 
  α1-antitrypsine deficiency 
  Hemochromatosis 
  Other 
 Viral hepatitis Hepatitis B (HBV) 
  Hepatitis C (HCV) 
 Other chronic liver diseases Vascular liver diseases (e.g. Budd-Chiari) 
  Polycystic liver disease 
Acute or subacute liver 
disease 
Viral hepatitis HBV 
HCV 
 Drugs Toxic mechanism or idiocynkrasia 
 Other toxic substance  e.g. amanita mushroom 
 Ischemia Ischemia  
 Other Pregnancy, trauma etc 
 Unknown etiology  
Liver tumors Primary Hepatocellular carcinoma (HCC) with 
cirrhosis 
  HCC without cirrhosis 
  Hepatoblastoma 
  Epitheloid hemangioendothelioma 
 Secondary Neuroendocrine tumor 
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Chronic liver diseases (CLD) 
The most common etiology behind CLD includes viral hepatitis, alcohol liver disease, 
cholestatic liver disease, autoimmune hepatitis, or metabolic liver disease.  All these CLDs 
usually progress over a long period of time towards cirrhosis of the liver.  In Finland, the 
most common type of CLD are cholestatic liver diseases, primary biliary cirrhosis (PBC), and 
primary sclerosing cholangitis (PSC), whereas viral hepatitis is not as common.  Small inner 
bile ducts get obliterated in PBC, which progresses to fibrosis and finally to biliary cirrhosis.  
The outer bile ducts may also have strictures in PSC.  Bilirubin and bile acids are left 
circulating in blood due to impaired bile flow.  PBC occurs usually in middle-aged women, 
whereas PSC affects mostly men that are younger.  About 80% of PSC patients have 
inflammatory bowel disease (IBD); either ulcerative colitis (UC) or Crohn’s disease (CD) and 
these intestinal diseases might occur years before the liver disease is diagnosed.  Still only 
about 3 to 8% of colitis patients may have PSC.  UC is far more common; 90% of PSC 
patients with IBD have UC and 10% have CD (23).  PSC is also associated with high risk for 
cholangiocarcinoma.  The most common indication for LT in children is biliary atresia.  
 
Acute or subacute liver disease 
Acute/subacute liver disease is a rare but very serious condition which can lead to ALF 
within 8 weeks or sometimes even within just a few hours, or subacute liver failure within 6 
months after the first symptoms.  These patients are usually generally healthy before sudden 
liver insufficiency caused by various etiological factors.  These factors in ALF include 
viruses or several toxic substances such as alcohol, drugs such as paracetamol, or other toxins 
such as from the amanita mushroom, but often the etiology remains unknown.  Necrosis of 
hepatocytes leads to multiorgan failure, and if the own liver does not regenerate, the patient, 
without LT, dies. 
 
Liver tumors 
Tumors of the liver can be benign or malignant.  The most common type of malignant liver 
tumor is the liver metastasis; however, metastatic liver disease is a contraindication for LT 
except in neuroendocrine tumors in very selected cases.  Hepatocellular carcinoma (HCC) is 
the most common primary liver tumor, in 70 to 80% of HCC cases occuring in a cirrhotic 
liver.  Only in very selected cases is LT possible for HCC with reasonable results.  
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Clinical evaluation of the patient with liver disease 
 
Clinical symptoms and signs 
Early-onset liver diseases may show only a few symptoms, or the symptoms can be aspecific, 
such as with fatigue, loss of appetite, malaise or mild fever.  Patients with a progressive liver 
disease may experience malnutrition and muscular atrophy resulting from the livers’ inability 
to synthesize albumin and other important nutrients.  Patients with a dysfunctional liver 
disease may suffer from anemia, leukopenia, and thrombocytopenia or decreased synthesis of 
coagulation factors.  Other symptoms are spiders, dilated small capillaries detectable on the 
skin of the arms, chest or neck.  Icterus may occur, a severe itching of the skin caused by 
increased levels of bile acids.  Changed patterns in sleep, cognitive difficulties, and 
disorientation may be early signs of encephalopathy.  Determining whether the symptoms 
relate to acute or chronic liver disease can be difficult, and symptoms may vary depending on 
the type of damage to the liver.  To find the correct etiology for liver disease, a thorough 
anamnesis includes family medical history, medications, use of herbal supplements, vitamins, 
IV drugs, and also information on possible intoxication, blood transfusions, travel to endemic 
countries, risky sexual behavior, and alcohol use (duration, amounts). 
 
Table 2.  Common symptoms and signs in chronic liver diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Severe fatigue 
Weight loss/muscle atrophy 
Loss of appetite 
Abdominal pain/nausea 
Pruritus (severe itching) 
Fever 
Icterus 
Hepatomegaly 
Splenomegaly 
Dark urine, pale stool 
Xanthomas (cholesterol) 
Ascites, varices (portal hypertension) 
Hemorrhage, bruising 
Encephalopathy  
Recurring infections 
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Laboratory tests 
When doubt exists regarding liver injury with damage to the hepatocytes or the biliary tree, 
several laboratory tests are necessary (Table 3).  The aminotransferases, ALT and AST, are 
liver enzymes both of which are reliable and sensitive as markers of liver injury representing 
hepatocellular necrosis.  Cholestatic disorders and the presence of biliary obstruction elevate 
serum bilirubin (Bil), ү-Glutamyltransferase (GT) and alkaline phosphatase (ALP).   
Bilirubin binds with albumin, and this unconjugated bilirubin is then synthesized into 
conjugated bilirubin that is secreted into bile.  GT has served widely as an index of liver 
dysfunction and marker of high alcohol intake.  Prolonged PT and high INR values are 
common markers in liver diseases and are warning signs for coagulation problems.  Low 
serum albumin or prealbumin reflects impairment in protein synthesis and may indicate CLD.   
 
Immunological tests may lead to correct diagnosis of the liver disease.  Biopsy of the liver is 
often needed and is the only reliable method in determining the level of liver fibrosis or 
cirrhosis.  The biopsy is done under local anesthesia in conjunction with ultrasound guidance.  
Radiological tests such as ultrasound (Doppler), CT or MRI are also useful in the diagnosis. 
Essential for PSC diagnosis is also endoscopic retrograde cholangiography (ERC). 
 
 
Table 3.  Common laboratory tests in liver diseases. 
 
Liver chemistry test Clinical implication 
 
Alanine aminotransferase (S-ALT) 
 
Hepatocellular damage 
Aspartate aminotransferase (S-AST) Hepatocellular damage 
Galactose elimination capacity (Gal t½) Hepatocellular damage 
Bilirubin (S-Bil, un/conjugated) Cholestasis, biliary obstruction 
ү-Glutamyltransferase (S-GT) Cholestasis, biliary obstruction 
Alkaline phosphatase (S-ALP) Cholestasis, biliary obstruction 
Prothrombin time (PT) Synthetic function 
International normalized ratio (INR) Synthetic function 
Prealbumin (S-Prealb) Synthetic function 
Albumin (S-Alb) Synthetic function 
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Cirrhosis of the liver 
Various pathological conditions of the liver may cause inflammation which results in necrosis 
of the hepatocytes and finally, over time, leads to fibrosis.  Normal liver tissue becomes 
replaced by scar tissue, and blood flow through the liver is obstructed.  This eventually 
results in cirrhosis, the end-stage of a liver disease.  The cirrhotic liver is smaller, darker, and 
contains fibrotic lumps.   
 
The incidence of cirrhosis continues to rise in Western societies (24).  Major etiological 
factors behind this are obesity, increased alcohol consumption, and an increased incidence of 
viral hepatitis (especially hepatitis C).  Almost all patients with cirrhosis show insulin 
resistance, and about one-third have diabetes.  Increased portal hypertension and decreased 
synthesis lead to life-threatening complications in cirrhosis which at the decompensated stage 
include severe ascites, variceal bleeding, hepatorenal and hepatopulmonar syndrome, and 
hepatic encephalopathy which then may result in coma.  Increased suspectibility to infections 
is a major concern, with spontaneous bacterial peritonitis (SBP) being the most common and 
life-threatening infection in cirrhosis (25,27).  Another severe complication of cirrhosis is risk 
for HCC (26).   
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Liver transplantation 
 
LT has established itself as the only curable treatment for end-stage liver disease; it aims to 
increase life expectancy as well as the quality of life.  All transplantations in Finland are 
centralized to HUCH.  Up to the end of 2012, 958 LTs had been done at an annual rate of 
about 50 to 55 LTs most recently (Figure 3).  Most LTs are done for adults, and the gender 
distribution is almost equal.  A potential candidate for LT may be any individual whose liver 
disease is either life-threatening or no longer is treatable by conservative methods.  LT may 
be considered for a patient with CLD if life expectancy is estimated to be less than a year.  
The complications and symptoms of endstage CLD, such as ascites, variceal bleeding, 
hepatorenal syndrome, recurrent infections, or encephalopathy, become more difficult to 
treat.  Severe itching or unbearable fatigue may be devastating to the patient and therefore 
determine the right time for LT.  
 
 
Figure 3.  Indications for LT in Finland during 1982-2012; total 958 transplantations. 
 
Source:  Finnish Liver Transplant Registry. 
 
Since PSC is associated with a high risk for cholangiocarcinoma, the correct timing for 
transplantation is crucial.  PSC and PBC are the most common indications for LT in Finland, 
whereas, compared to many other countries, viral hepatitis is an infrequent indication.  The 
third most common indication in Finland nowadays is alcohol cirrhosis, although still only 
about 1% of such alcohol cirrhotic patients may receive LT.  Patients with alcohol cirrhosis 
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must have no other serious organ failures and must observe strict abstinence from alcohol.  In 
the case of ALF, it may be difficult to determine whether the liver will recover without 
transplantation.  Molecular Absorbent Recirculating System (MARS) treatment reduces 
bilirubin and serum creatinine levels.  MARS has been successfully used in Finland and 
allows a longer waiting time for LT (28).  In the case of liver tumors, a contraindication for 
LT is tumor spread outside the liver.  Criteria for LT for tumors follow the Milan criteria:  in 
the liver, one HCC under 5 cm in diameter is accepted, or at maximum 3 HCC nodules if 
each is under 3 cm. 
 
Pretransplant evaluation 
Several medical and social evaluations allow determination as to whether the candidate is 
suitable for LT and whether timing for LT is appropriate.  A wide range of laboratory tests 
assess liver function and ensure an exact diagnosis of the liver disease.  Dental evaluation and 
eradication of all potential infectious foci has been routine since the early 1980s when the LT 
program started in Finland.  At a multidisciplinary meeting after all the evaluations, a 
candidate for LT may be placed on a waiting list for a transplant.   
 
The waiting time for LT is among the shortest in Finland but differs between chronic and 
acute LT candidates.  The average wait for CLD is less than 2 months, but for ALF the wait 
is a mean 4 days with a median of 2 days.  Allografts for LT come from cadaveric, brain-dead 
donors. 
 
MELD score 
Several classifications are used to assess the severity of liver disease.  The Model for End-
Stage Liver Disease (MELD) score predicts the risk of dying without LT (29) and is used for 
allocation in the USA and in some European countries but not in Finland.  It was originally 
derived in a series of patients undergoing elective transjugular intrahepatic portosystemic 
shunt (TIPS) procedures.  MELD score is assessed by the values of bilirubin, INR, and 
creatinine by an equation calculated as      
 
9.57 × Log creatinine (mg/dl) + 3.78 × Log bilirubin (mg/dl) + 11.20 × Log INR + 6.43 
  
The conversion factor to calculate µmol/l for creatinine is 88.4 and for bilirubin 17.1.  The 
value for MELD score ranges from 6 to 40.  For candidates on dialysis, defined as having two 
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or more dialysis treatments within the preceding week; the MELD score calculator will have 
their serum creatinine level automatically set to 4.0 mg/dl.   
  
The operation 
When a donor is available, selection of the most suitable recipient for LT is based on blood 
type, size of organ, and medical urgency.  To ensure the shortest cold ischemia time, 
operations for both the donor and the recipient partly overlap.  The operation for the LT 
recipient includes removal of the disfunctioning liver and transplantation of the new liver.  
The blood vessels and the bile ducts of the recipient and the donor liver are anastomized, and 
the gall bladders from both the donor and the recipient are removed.  The operation takes 
from 5 to 16 hours. 
  
Post-transplant monitoring 
The LT recipient stays from one to 4 days in the ICU and up to 2 or 3 weeks on the ward 
before discharge.  After this, follow-up is organized in cooperation between the specialized 
health care of the patient’s own hospital district and the transplant unit according to protocol.  
Close monitoring ensures early detection of allograft dysfunction, and possible drug side-
effects can also be noticed when follow-up is frequent. 
 
Immunosuppressive and other drugs 
Following LT, the recipients’ immune system recognizes the transplanted organ as foreign, 
activating a complex immune response that would result in graft rejection.  This 
immunological response is mainly mediated by T-lymphocytes.  The rejection response can 
be divided into four phases:  antigen recognition, lymphocyte activation, lymphocyte 
proliferation, and graft inflammation (30).  To prevent rejection, recipients of LT face 
lifelong immunosuppression.  The cornerstone of immunosuppression is calcineurin 
inhibitors (CNI); either cyclosporine-A (CsA) or tacrolimus (TAC). Newer 
immunosuppressants, sirolimus or everolimus, which belong to the drug group mammalian 
target of rapamycin (mTOR), may serve as a substitute for CNI.  Corticosteroids and 
antimetabolites; azathioprine or mycophenolate mofetil; are often combined with CNI or 
mTOR.  
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During longer follow-up, total immunosuppression predisposes to infections and 
malignancies; the challenge is to find optimal immunosuppressive therapy that prevents 
rejection with the least number of side-effects (31,32).  The most common adverse effects 
during different types of immunosuppressants are provided in Table 4. 
 
Table 4.  Frequent side-effects in different immunosuppressive drug groups.  Each drug also 
possesses specific side-effects in addition to those listed in the table.  Modified from the 
source (33). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CsA, cyclosporine-A 
TAC, tacrolimus 
Cort, corticosteroid 
AZA, azathioprine  
MMF, mycophenolate mofetil 
mTOR, mammalian target of rapamycin (sirolimus or everolimus) 
-, not reported; +, rarely reported; ++, commonly reported; +++, very frequently reported;  
?, data scarce or discordant 
* See reference no.  (34) 
 
Adverse effect CsA TAC Cort AZA MMF mTOR 
 
Alopecia - + - - + - 
Bone marrow suppression + + - +++ ++ + 
Gastrointestinal toxicity + ++ ++ + +++ + 
Gingival overgrowth +++ + - -  - (?) * 
Hepatotoxicity + + - ++ - + 
Hirsutism + - - -  - - 
 
Hyperglycemia/diabetes + ++ +++ - - + (?) 
Hyperlipidemia ++ + ++ - - +++ 
Hypertension +++ ++ +++ - - + 
Impaired wound healing - - + - - ++ 
Myalgia/arthralgia - - - - + ++ 
Nephrotoxicity +++ +++ - - - +  
Neurotoxicity ++ ++ + - + - 
Osteoporosis + + +++ - - - 
Peripheral edema - - ++ - - ++ 
Pneumonitis - - - - - + 
Skin/mucosal lesions - + 
rash 
++ - + ++acne, 
oral ulcers 
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CNIs may cause side-effects which include nephro- and neurotoxicity and infections.  
Nephrotoxicity may lead to post-transplantation diabetes, and a great concern with CNI and 
corticosteroids is a risk for cardiovascular diseases (35).  Cardiovascular medications are 
therefore often prescribed to maintain normal blood pressure levels; a selective ß-blocker, 
diuretics, an ACE-inhibitor, or calcium channel blocker may be used.  Statins and other 
cholesterol-lowering medications are also needed after LT to protect against cardiovascular 
risk (36).   
 
Bone loss may already be occurring during CLD, especially among post-menopausal women, 
and risk for osteoporosis rises further by the use of CNIs and corticosteroids (37).  
Immunosuppression predisposes also to alveolar bone loss (15,16).  To prevent osteoporosis 
and fractures that might follow, vitamin D, calcium derivatives, bisphosphonates, and also 
new biological drugs are useful (38).  Bisphosphonate use increases risk for osteonecrosis of 
the jaws; therefore before LT, elimination of infected teeth aims to lower risk for serious 
necrosis of the jaws (39).  
 
Infectious complications 
Immunosuppression considerably weakens the host’s ability to fight infections.  Recipients of 
LT are therefore at risk for all types of infections (4).  A wide range of bacterial, viral (e.g. 
cytomegalovirus (CMV) infection), or fungal infections such as Candida and Aspergillus can 
be life-threatening among immunocompromised hosts (5). The most common cause for 
mortality after LT is infectious complications.  Risk is highest during the early stages after 
LT when immunosuppression is the strongest.  To minimize risk for post-transplant infection, 
all potential infection foci should be eradicated before transplantation. This includes 
eradication of infectious dental foci. 
 
Quality of life after transplantation 
Liver transplantation aims to improve quality of life.  LT recipients’ quality of life is equal to 
that of the general population (1).  Younger LT recipients often, a mere 6 months after 
transplantation, have returned to work or to their studies. 
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Oral cavity 
 
The oral cavity is covered by a moist lining called the oral mucosa over the palate, the 
palatine arches, the uvula, the inner cheeks, and the floor of the mouth as well as the lips.  
Inside the oral cavity are the tongue and the teeth with their supporting structures.  Food 
enters this uppermost part of the gastrointestinal tract, and digestion begins with the effect of 
the salivary enzymes.   
 
Mucosal integrity 
 
The normal oral mucosa consists of an outer stratified squamous epithelial layer and an inner 
lamina propria made mainly of fibroblasts.  The basement membrane is situated between 
these two structures. Oral mucosal health is dependent on iron, folic acid, and vitamin B12.  
Depletion of these nutrients may compromise mucosal integrity and leave the oral cavity 
vulnerable to becoming a port of entry for diseases. 
 
Saliva 
 
Saliva is fundamental to the well-being of the oral cavity.  This oral fluid is secreted from the 
salivary glands that include the parotid, submandibular, sublingual, and the minor labial 
salivary glands.  Every day we swallow approximately one liter of saliva.  The submandibular 
glands are mainly responsible for the secretion of unstimulated whole saliva, whereas the 
parotid gland secretes most of the stimulated saliva.  Oral stimuli, both masticatory and 
olfactory, trigger both the sympathetic and parasympathetic nerves that affect the salivary 
glands.  Different stimuli result in different flow rates and a different composition of saliva; 
2% citric acid causes the maximum stimulus, and it is often used in salivary clinical research 
(40).  Salivary flow rate has huge individual and gender variation, and the time of day can 
also affect salivary flow.  Our daily saliva follows circadian rhythms, and even minor 
temperature changes seem to affect salivary flow rates (41).  Aging as such does not affect 
saliva secretion, but in older individuals lowered salivary flow rates are mainly due to various 
anticholinergic and xerogenic drugs.   
 
Saliva composition is very complex.  It contains water, electrolytes, various cells and micro-
organisms, proteins, amino acids, enzymes, lipids, and DNA/RNA.  Digestion starts already 
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in the mouth during mastication via salivary enzymes.  When chewing has stimulated the  
salivary flow, then also more enzymes such as amylase and peroxidase are secreted.   
 
Saliva has many functions and properties.  Saliva lubricates the oral surfaces, and a sufficient 
volume is necessary for cleansing the oral mucosa and tooth surfaces of oral microbes.  In 
addition to the clearance of microbes, saliva also has antimicrobial properties to fight oral 
diseases.  Ability to neutralize acids, or buffering capacity, is an important function of the 
saliva and correlates with the salivary flow.  Saliva is supersaturated with phosphate, calcium, 
and fluoride ions, enabling remineralization of the enamel.  The normal pH of saliva is 
around 7, and whenever the pH falls below 5.5, demineralization occurs on the enamel 
surface.  Most fuzzy drinks are very acidic, and if consumed on a daily basis, can cause 
severe erosion of the teeth (42).   
 
A sufficient amount of saliva is important in speaking and in wearing dentures.  Saliva also 
protects the taste receptors within the taste buds in the tongue, and normal salivary flow is 
required for the sense of taste.  Salivary hypofunction thus helps explain why food tastes 
different to different people. 
   
Oral microbiota 
 
The warm and moist environment of the oral cavity favors the existence of many different 
oral microbes.  Distinct oral habitats, such as the teeth, gingival crevice (the space between 
the tooth and the gingiva), tongue, cheek, hard and soft palate, the tonsils, and the pharynx, 
may harbor site-specific bacteria, viruses, and fungi that form the oral microbiota or oral 
microbiome. 
  
Bacteria 
One estimate is that the total number of bacteria in the mouth is around 6 billion.  Thus far, 
hundreds of species of oral bacteria are known (43), but novel species are continually 
discovered by 16S rDNA gene sequencing (44).  The pellicle – consisting of a thin layer of 
protective salivary glycoproteins interacting with the enamel – also acts as a substrate on 
which bacteria attach.  The ability of bacteria to stick onto hard or soft oral surfaces then 
creates a perfect environment for the plaque bacteria to mature.  Dental plaque is referred to 
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as dental biofilm (45), and this rich, complex network of bacteria forms microbial 
communities which divide into smaller micro-niches (46).   
 
Most oral bacteria are commensal, benefiting both the host and the organism itself, and in 
small numbers, the bacteria are harmless.  A shift from health to disease occurs when the 
equilibrium of the ecological balance between the host and oral micro-organisms is disturbed.  
This change in population dynamics may result from poor oral hygiene, aging, diet, genetic 
factors, or underlying systemic conditions in the host which in turn can predispose the host to 
oral diseases (47).   
 
Although normal oral flora is difficult to define (Table 5), between healthy and diseased oral 
cavities are distinct differences.  The primary colonizers in the oral cavity are gram-positive 
aerobes or facultative anaerobes such as Streptococcus and Actinomyces species.  Mature 
plaque contains mainly gram-negative anaerobes like Fusobacterium and Treponema.  
Various bacteria possess various virulence factors and geographical variations.  
Streptococcus viridans is part of the normal oral flora and can also occur on intestinal mucosa 
and on the skin.  These α-hemolytic bacteria cause about 40% of endocarditis cases, and they 
may also cause bacteremia or meningitis in immunocompromised hosts.  Recently, research 
has linked S. viridans to SBP infections in CLD patients (48). 
 
Fungi 
Oral fungi, also part of the normal oral microbiota, are usually harmless and superficial in 
healthy individuals with an innate immune response.  The most typical are Candida albicans, 
which accounts for about 50% of cases.  C. albicans grows mainly on mucosal surfaces: the 
inner cheeks, tongue, and the floor of the mouth, but can be cultivated from porous denture 
surfaces.  Interest is increasing in research on non-albicans strains which are highly resistant 
to common antifungal therapies (49).  C.glabrata produces the highest mortality rate due to 
its hemolytic activity that allows for tissue invasion and increased risk for bloodstream 
infections in immunocompromised hosts (50,51). 
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Viruses 
The following viruses belonging to the Herpes virus family can occur in the oral cavity:  
herpes simplex virus types 1 and 2 (HSV1, HSV2), Varicella Zoster virus, Epstein Barr virus 
(EBV),  and CMV.  EBV and CMV are common in organ-transplant recipients and also occur 
in the oral cavity (Table 6).  They may be associated with oral ulcers, oral hairy leukoplakia, 
and other infectious oral mucosal lesions (52).  HSV-1 and HSV-2, however, are still most 
common viruses affecting oral health; they cause recurrent herpetiform ulcerations or cold 
sores (53).  Human papilloma virus (HPV), specifically HPV type 16, has been linked to head 
and neck squamous cell carcinoma (SCC) (54). 
 
Table 5.  Characteristic species of oral microbiota. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMV, cytomagalovirus 
EBV, Ebstein Barr virus 
HBV, hepatitis B virus       
HCV, hepatitis C virus 
HIV, human immunodeficiency virus 
HPV, human papillomavirus 
HSV1, herpes simplex virus type 1 
HSV2, herpes simplex virus type 2 
Micro-organism Examples of species 
Bacteria  
   Cariogenic Streptococcus viridans group:  S. mutans, S. mitis,  
S. sobrinus, S. salivarius, S. oralis, S. sanguis 
Lactobacillus, Actinomyces 
   Periodontal Porphyromonas gingivalis, Prevotella intermedia, 
Treponema denticola, Fusobacterium nucleatum, 
Aggregatibacter actinomycetemcomitans,  
Tannerella forsythia 
Fungi Candida albicans 
Non-albicans Candida:  C. glabrata, C. parapsilosis,  
C. krusei, C. tropicalis 
Viruses CMV, EBV, HBV, HCV, HIV, HPV, HSV 
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Signs and symptoms involving the mouth 
 
Caries 
Caries or tooth decay is the most common and widespread infectious dental disease 
worldwide, and the risk for dental diseases, especially caries and periodontitis, increases as 
people live longer and retain their teeth for a longer period of time.   
 
Nutrition, tooth anatomy, quantity and quality of saliva, host response, and typical cariogenic 
bacteria all play a role in the multifactorial etiopathogenesis of caries (55,56).  
Hyposalivation associates with systemic diseases, like diabetes, rheumatic diseases, and 
asthma, which are considerable risk factors for caries.  Streptococcus mutans, belonging to 
the S.viridans group, is an acidogenic plaque pathogen that initiates caries formation by 
fermenting carbohydrates into acids.  Frequent consumption of sugars (especially sticky 
sweets) lowers the salivary pH and favors Lactobacillus species involved in caries 
progression.  An “acid attack” occurs every time we eat or drink, and this may cause 
demineralization of the enamel, leading to tooth decay.  Initial carious lesions limited to the 
enamel surface can be reversed by remineralization under normal salivary conditions; 
phosphate, calcium, and fluoride ions in the saliva “rebuild” the unique structure of the 
enamel, and the pH rises.  High S.mutans and Lactobacillus counts, low salivary flow, and 
poor buffering capacity of the saliva elevate the risk for demineralization, and cavitation may 
extend into the dentinal layer.  Untreated carious lesions may progress deeper into the tooth 
structure.  If the carious pathogens reach the inner pulp containing the blood vessels and 
nerves, an  endodontic infection - infection of the root canal system - occurs. 
  
Gingivitis 
If the biofilm formation is not disturbed, bacterial plaque accumulates on teeth.  Gingivitis or 
gum disease refers to the inflammation of the gingiva that surrounds the tooth; it manifests as 
swollen, red gums that easily bleed.  Gingivitis prevalence is estimated to be around 90%, but 
as with caries, gingivitis can be prevented with good oral hygiene that includes brushing and 
cleaning in between the teeth in order to limit the bacteria to small amounts. 
 
Periodontitis 
Gingivitis may lead to periodontitis when the tooth-supporting structures produce a more 
serious form of cellular inflammatory response to the bacterial deposits on teeth.  The 
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pathogenesis of periodontitis is a complex cascade involving periodontal pathogens that 
trigger the secretion of matrix metalloproteases (MMPs), IL-1, TNF-α, and other 
proinflammatory cytokines that result in destruction of the collagen attachment between the 
tooth and the alveolar bone (57).  MMPs have long been recognized as the key inflammatory 
markers found in saliva or in the gingival crevicular fluid, resulting in periodontitis when 
periodontal pathogens are also present (58).  Elevated levels of MMPs, especially MMP-8, 
thus cause deterioration of the tooth-supporting structures, which may result in tooth loss.   A 
host response in periodontitis is crucial, since genetic mutations in the host may result in a 
more aggressive form of periodontal disease.  Significant attachment loss appears clinically 
as deepened (≥ 4 mm) periodontal probing depth, and radiographically as severe alveolar 
bone loss.  Typical periodontal pathogens are gram-negative anaerobic bacteria found in 
subgingival crevices (see Table 5).  In deeper periodontal pockets, the number of bacteria are 
higher.   
 
Untreated caries lesions or periodontal disease may cause abscesses that, in a healthy 
individual, remain local, due to the normal immunological function of the lymphocytes.  In 
contrast, in immunocompromised hosts, the oral infections may spread through inflamed 
gums to the general circulatory system, causing sepsis or lung or brain abscesses which can 
be fatal.  Periodontal disease is linked to many systemic diseases, such as diabetes, low birth 
weight, and atherosclerosis (19,20,59-61). 
 
Oral mucosal lesions (OML) 
When mucosal integrity is compromised, a risk arises for oral mucosal lesions (OML), 
grouped by color into red, white and pigmented (62).  OMLs are often associated with 
systemic conditions or diseases; Table 6 shows one practicable way of classifying these 
lesions. 
 
An oral mucosal ulcer penetrates the mucosal epithelium, reaching the inner connective 
tissue containing the blood vessels.  Differential diagnosis of oral ulcers is crucial.  If an ulcer 
does not heal within two weeks, the possibility exists that it may be malignant, since oral 
cancer and other malignant tumors in the oral region may manifest as ulcers.  The most 
common type of oral lesion is the recurrent aphtous ulcer, which can be classified into 
idiopathic or secondary.  The secondary form is associated with CD, UC, certain medications  
(metotrexan, non-steroidal anti-inflammatory drugs [NSAID], ß-blockers), or deficiency of 
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iron, folic acid, or vitamin B12.  Predisposing factors include stress, trauma, infections, and 
food allergies.  Recurrent aftous ulcers occur both in health and in disease, but the ulcers 
associated with systemic diseases can be more resistant to treatment. 
 
 
Table 6.  Classification of oral mucosal lesions.  Modified from the source (63). 
 
CMV, cytomegalovirus 
EBV, Ebstein Barr virus 
HCV, hepatitis C virus 
HPV, human papillomavirus 
HSV, herpex simplex virus 
IBD, inflammatory bowel disease 
SCC, squamous cell carcinoma 
 
 
 
 
Atrophic tongue is often a consequence of nutritional deficiencies such as avitaminosis of 
B12, or folic acid, or depletion of iron.  The tongue is bright red and it has a smooth surface 
due to disappearance of filiform papillae.  Predisposing factors, like spicy foods and irritating 
oral health products such as toothpastes containing natrium layryl sulfate should be avoided if 
they cause symptoms.   
Drug or allergy induced Drug induced gingival overgrowth, galvanic reactions (e.g. rough 
amalgam filling) 
 
Hyperplasia Candida infections, ill-fitting denture, poor oral hygiene, trauma 
 
Infectious lesions CMV, EBV, HCV, HPV, HSV 
 
Lesions of the tongue Atrophic tongue, fissured tongue, geographic tongue, hairy 
leukoplakia, median rhomboid glossitis 
 
Manifestations of derma-
tological diseases 
 
Discoid lupus erythematosus, Erythema multiforme, oral lichen 
planus, pemfigoid 
Precancerous and malignant 
lesions 
Atrophic/erosive lichen, erythroplakia, leukoplakia,  
oral cancer/SCC 
 
Ulcers Atrophic Candida, CMV, dermatitis herpetiformis, discoid lupus 
erythematosus, EBV, Erythema multiforme, HSV, IBD, oral 
lichen planus, pemfigoid, pemfigus, recurrent aphtous ulcer, SCC, 
syphilis, trauma/radiation, Wegener’s granulomatosis 
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Fissured tongue is a common, usually symptomless lesion of the dorsal surface of the tongue 
that is associated with dry mouth.  The fissures can be several millimeters deep, and may 
harbor Candida and other microbes.  Careful cleaning of the tongue surface is necessary.  
Geographic tongue is a benign condition that may exist together with fissured tongue, 
psoriasis, or Reiter’s syndrome.  It is characterized by reddish, atrophic patches that alternate 
between the dorsal and lateral tongue surfaces.  Its  etiology is unknown, but possible triggers 
are stress, infections, genetic predisposition, or allergies.  Hairy tongue consists of long 
papillae on the dorsum of the tongue.  Predisposing factors include smoking, poor oral 
hygiene, hyposalivation, or candidosis.  Median rhomboid glossitis is characterized by a red 
area on the midline of the dorsal surface of the tongue as a result of papillary atrophy. 
 
Candida species are evidently true opportunistic pathogens, since they cause oral infection 
when the host has an underlying predisposing systemic condition, as in HIV infection, 
endocrine disorders, nutritional deficiencies, or treatment with broad-spectrum antibiotics, or 
during immunosuppression (64).  In immunocompromised patients, fungal infections are 
associated with high mortality (65).  Local predisposing factors include poor oral hygiene, 
lowered salivary flow, and inhaled glucocorticoids.  Stinging, burning sensation in the mouth, 
and also malodor are typical clinical symptoms of oral candidosis.  Four primary forms can 
be detected clinically: (a) acute pseudomembranous candidosis, (b) chronic erythematous 
candidosis, (c) acute erythematous candidosis, and (d) chronic hyperplastic candidosis.  A  
secondary form includes denture stomatitis, angular cheilitis, and median rhomboid glossitis; 
these often occur if dentures need repair.  Inflamed palatal mucosa under an upper full 
denture is characteristic of denture stomatitis and the corners of the mouth are involved in 
angular cheilitis.  Treatment includes topical antifungals, repair of dentures or new dentures, 
and proper oral hygiene.   
 
Early detection of precancerous oral lesions is important since oral cancer is associated with 
high mortality, making regular follow-up of these lesions vital.  Precancerous or potentially 
malignant OMLs include oral lichen planus (OLP), leukoplakia, erythroplakia, and ulcers 
(66).  Lichen ruber planus is a chronic, inflammatory, autoimmune disease of the skin, scalp, 
nails, and mucous membranes with its etiology unknown (67).  Oral lichen planus (OLP) is 
5 to 10 times as common and complex as the skin form of the disease.  Other recognized 
forms of OLP are striated, papular, plaque, atrophic/erosive, ulcerative, or bullous (68).  
Regular follow-up of these lesions is important, since the atrophic/ulcerative/erosive form of 
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OLP may become malignant (69).  A definite diagnosis requires a biopsy from the lesion.  
OLP is an idiopathic condition, whereas a lichenoid reaction may be triggered as a reaction to 
an outside source such as allergy to restorative tooth material, a rough tooth filling, a drug 
reaction, HCV, or graft-vs-host disease (70-72).  These similar entities are sometimes hard to 
differentiate from each other.  Topical ointments containing steroids, calcineurin inhibitors, 
and 0.1% triamcinolone acetonide have ameliorated symptoms and expedited recovery 
(68,73).  OLP has been associated with liver disease (67).    
 
Leukoplakia is defined as a white patch, either verrucous or nodular, that will not wipe away 
from the surface it adheres to and cannot be characterized clinically or pathologically as any 
other definable disease (74). Differential diagnosis includes burns, frictional or tobacco 
(hyper) keratosis, linea alba, OLP, lichenoid reactions, Candida infection, or hairy 
leukoplakia.  Smoking is a strong risk factor for this lesion; concomitant use with alcohol 
increases the risk even more (75).  Candidosis and human papillomavirus (HPV) associate 
with leukoplakia, and at risk sites (floor of mouth, ventrum of tongue, lower lip), up to 30% 
of these heterogenous group of lesions can be malignant (76).   
 
Erythroplakia is a rare lesion that appears more red than its surroundings.  It is usually 
located on the floor of the mouth or on the tongue, and 90% of erythroplasias are dysplastic, 
so risk for SCC is high.  The etiology behind it is unclear, but smoking and heavy alcohol use 
increase risk.  Atrophic Candida infection or contact allergy can be mistaken for 
erythroplasia, and diagnosis is by biopsy. 
 
The most common type of oral cancer is SCC, derived from the stratified squamous 
epithelial layer of the oral mucosa.  Its prognosis is still very poor (77).  Healthy and 
pathological sites harbor different types of microbiota, and recent evidence has emerged that 
the pathogenesis of cancer in the oropharyngeal cavity is associated with oral microbes (78).  
Oral microbes like S. mutans have the ability to degrade ethanol into acetaldehyde, a strong 
carcinogen.  Poor oral hygiene, candidosis, and smoking and alcohol use together therefore 
increase the risk for oral cancer (79).  Other risk factors include the erosive or atrophic form 
of OLP, HPV (types 16,18), sunburn, and immune deficiencies (54,69). 
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Xerostomia and hyposalivation 
Xerostomia refers to a subjective feeling of dry mouth in contrast to objectively measured 
hyposalivation which by definition (80) is diagnosed when both unstimulated and stimulated 
salivary flow rates are significantly reduced.  The thresholds for hyposalivation are:  
unstimulated saliva <0.1 ml/min and stimulated saliva <0.7 ml/min.  A feeling of dry mouth 
can exist without hyposalivation’s being objectively assessed (81). 
 
Systemic diseases affect salivary flow by differing mechanisms (82).  Diabetes causes 
disturbance of the electrolyte balance, resulting in dehydration (83).  Physiological and 
hormonal changes during menopause can also affect salivary flow (84).  Diseases of the 
salivary glands such as sialoadenitis, sarcoidosis, and Sjögren’s syndrome cause salivary 
hypofunction (85,86).  Irradiation to the head and neck region may cause permanent 
destruction of the salivary glands, resulting in total oral dryness (87).   
 
Drugs are the main cause of xerostomia, with most medications and drug types found to be 
xerogenic.  These include antihypertensives, antidepressants, anxiolytics, appetite 
suppressants, decongestants, and antihistamines (82,88,89).  Emotion, neurosis, systemic 
diseases, infections, and tumors may also be responsible for xerostomia, which can be 
devastating to a patient (81).  Eating, talking, and wearing dentures all become difficult when 
saliva is insufficient (90,91), and in a dry mouth, risks for all oral diseases increase.  New 
biological drugs, such as rituximab and anti-TNF-α are promising new drugs in the treatment 
of hyposalivation (92,93). 
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Burning mouth syndrome (BMS) 
This condition, BMS, is also dry-mouth-related with population prevalences between 1 and 
10% (94).  It is characterized as an oral burning sensation in the absence of any organic 
disorders of the oral cavity (95).  As it is most often found in middle-aged women (96), 
hormonal changes may predispose to oral burning (84,97).  A variety of other conditions such 
as nutritional deficiencies, diabetes, and medication side-effects contribute to a secondary 
form of BMS (98); this is the most common type of BMS.  In the primary or idiopathic form 
of BMS, no local or systemic causes can be identified, so neuropathological mechanism may 
be the underlying cause.  BMS has a strong association with psychological disorders. 
 
Dysphagia 
Difficulty in swallowing, or dysphagia, is often accompanied by xerostomia or 
hyposalivation, but the cause may be esophageal motility disorder (99).  Talking, eating, and 
taking medications may become difficult with this unpleasant symptom.  Esophageal 
overgrowth of Candida may also cause dysphagia, which can result in nutritional problems 
(100).  In such cases, treatment of candidosis by antifungals is necessary. 
 
Dysgeusia 
Altered taste sensation or dysgeusia is not as common as the other dry-mouth-related 
subjective oral symptoms, but this clinical taste phantom has been associated with BMS 
(101).  Taste perception is centralized to the tongue and its papillae.  In a dry mouth, function 
of the papillae is lessened, and the sensation of taste diminishes.  Some medications may alter 
taste, and denture wearers may also face a risk for dysgeusia which can lessen quality of life 
(89).  Candidosis has also been associated with this disorder (100). 
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Liver diseases and the mouth 
 
Patients with CLD have generally poor oral health (Table 7).  In end-stage liver disease, 
cirrhotic patients are susceptible to infections which can be fatal.  Impairment of coagulation 
causes a significantly increased tendency for bleeding (12,102).  Professional cleaning of 
teeth or tooth extraction may follow, with extensive bleeding that can be life-threatening if 
not treated properly (103).  In this setting, dental treatment of these medically compromised 
patients is often complicated, and the most severe liver disease patients should thus be 
referred to a local hospital that includes hospital dentistry.    
 
Teeth 
Early childhood liver disease, typically biliary atresia, can cause discoloration of the 
developing permanent teeth (104,105).  Increased bilirubin levels in cholestasis color the 
dentinal layer greyish-green, although microscopic analysis has shown that the outer enamel 
maintains its translucency (106).  The teeth appear to be green in color.  Developmental 
disturbances may also cause enamel hypoplasias in the teeth, which appear as white or 
yellow patches. 
 
The gastric reflux common in liver diseases may have harmful effects on the teeth due to 
acidic regurgitation.  Gastric fluid is very acidic, its pH is around 2 and tooth erosion occurs 
when the surface pH falls below 5.5.  Hyposalivation caused by several medications can 
make erosive wear even greater (42).  Dental erosion can also be caused by extrinsic factors;  
it is a common manifestation in alcoholic liver disease, since the pH of most alcoholic 
beverages is low (107).  Attrition has been reported in liver disease patients, this being  
another condition that wears down the teeth and may cause sensitivity due to exposed nerve 
endings in the dentin.  Its cause is bruxism or grinding of the teeth, and lowered salivary flow 
causes more depletion of the dental material.  Sometimes it is difficult to differentiate 
between attrition and erosion, since these disorders may exist simultaneously.   
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Table 7.  Oral symptoms and signs in chronic liver diseases. 
 
 
CMV, cytomegalovirus 
HCV, hepatitis C virus 
IBD, inflammatory bowel disease (associated with primary sclerosing cholangitis) 
PBC, primary biliary cirrhosis 
 
 
 
 
Oral manifestation Examples of etiology/cause Reference 
 
 
Petechiae, hematoma, gingival bleeding, 
reduced wound healing 
 
 
Hemorrhagic changes/coagulation 
disturbances 
 
(12,102,103,108-113) 
Discolorations of teeth  Biliary atresia (104-106) 
 
 
 Periodontal disease Anemia, neutropenia, IBD 
 
(114-117) 
 Tooth decay (caries) Hyposalivation/xerostomia, 
alcoholic liver disease 
 
(118-120) 
 Erosion 
 
Alcohol cirrhosis (107) 
Oral lichen planus 
 
HCV, PBC (13,73,121-123) 
Leukoplakia 
 
HCV (121) 
 Mucosal ulcers IBD, PBC, Bechet’s disease 
 
(110,124-126) 
 Candidosis Xerostomia (110,121,127) 
 
Angular cheilitis 
 
Cirrhosis of the liver (110,127) 
 Pyostomatitis vegetans 
 
IBD (128) 
 Herpetic ulcerations 
 
CMV, HCV (110) 
Glossitis, smooth tongue,  
atrophic tongue 
Alcohol liver disease, nutritional  
deficiencies 
 
(129,130) 
Fissured tongue HCV, IBD,  hyposalivation/ 
xerostomia 
 
(124,159) 
Xerostomia HCV, PBC, IBD 
 
(11,85,131-133) 
 Halitosis Xerostomia, IBD (134) 
 
Sjögren’s syndrome HCV, PBC 
 
(131-133) 
Parotid gland enlargement/ 
sialoadenitis 
Alcohol cirrhosis, HCV (85) 
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Oral mucosa 
CLD patients often suffer from malnutrition and anemia.  Depletion of iron and avitaminosis 
of B12 and folic acid promote susceptibility to OMLs (135,136) of which, several kinds  
occur in patients with liver diseases.  Elevation in bilirubin manifests also in the oral cavity, 
making the oral mucosa yellow-brownish in color.  The lowered immune response in these 
patients also predisposes to candidosis (119,121).  Chronic, active hepatitis or PBC has a 
strong correlation with OLP (123).  Especially the erosive form of OLP has been associated 
with CLD (122).  Because the oral mucosal membrane is very similar to the inner lining of 
the intestines, similar lesions may be found in the oral cavity and in the other parts of the 
gastrointestinal tract.   
 
Oral lesions associated with IBD 
Both IBDs share similar oral manifestations, but the oral lesions occur more frequently with 
CD with varying prevalences ranging from 0.5 to 80% (137).  Certain typical lesions such as 
recurrent aphtous ulcers, may appear months or even years before IBD is diagnosed since the 
early symptoms of this disease are often mild.  Therefore, recognition of these lesions is 
crucial since the dentist may be the first clinician to suspect UC or CD. Consultation with a 
gastroenterologist is indispensable in the overall treatment of these patients (134). 
 
Periodontitis, which is also a chronic inflammatory disease, has been associated with both 
UC and CD (117).  CD patients may experience disease-specific oral lesions such as diffuse 
buccal mucosal swelling, typical cobbler-stone-like oral mucosa, deep linear ulcerations in 
the buccal sulci, mucosal tags, or candidosis (138).  Other common features include swollen 
lips or facial skin.  The mouth can be sore from inflamed gums that appear granulomatotous. 
Sometimes changes in the anemic profile as often manifested in periodontal disease, could 
lead to the right diagnosis of CD (114). 
 
Pyostomatitis vegetans manifests as painful ulcerations or multiple erythematous pustules in 
the oral mucosa and it is considered a highly specific marker of IBD; these erosive changes in 
the oral mucosa can be early signs of UC (128).  
 
Several medications may affect salivary flow, and CLD patients may therefore suffer from 
xerostomia and from many other dry-mouth-related symptoms and signs (85,131). 
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The liver transplant patient and the mouth 
 
Pretransplant dental evaluation 
 
Infections of the oral cavity are usually frequent among patients waiting for an LT (9,18,139). 
The main purpose of dental evaluation is to prevent bacteremia and sepsis that could arise 
from untreated oral or dental sources, because in these immunosuppressed patients the 
leading cause for morbidity and mortality is infection (140).  When planning dental 
treatment, consultation with the treating physician is most important. 
 
Infectious dental foci 
The focal theory in dentistry was first introduced by WD Miller in the 1890’s (141).  By 
definition, “a focal infection is a localized or generalized infection caused by the 
dissemination of microorganisms or toxic products from a focus of infection in various 
organic districts, including the oral district”.  Oral bacterial flora may be transferred to the 
blood stream by invasive dental procedures, tooth brushing, or chewing, but poor oral health 
and frequent dental infections clearly worsen the development of bacteremia (142).  In 
healthy individuals, the host's reticuloendothelial system clears the pathogens from the blood, 
but in immunocompromised hosts, risk for focal infections is higher.   
 
Systemic diseases and conditions such as diabetes, cardiovascular diseases, infectious 
endocarditis, cerebral abscesses, lung infections, premature birth, and several other conditions 
have been linked to oral infections, specifically to periodontal disease, although this theory is 
still controversial (19,20,59-61,143).  Oral infections seem to worsen the progression of 
several systemic diseases, but the relationship is bidirectional in that systemic diseases also 
aggravate oral health status.  
 
Any infections of the oral cavity can be regarded as potential infection foci.  Infectious oral 
and dental foci include the oral mucosa, teeth with their supporting structures, and the jaws.  
Panoramic tomography (PTG) is necessary, since symptomless, chronic infections may hide 
far back in the jaws.  
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Current guidelines 
Most of the world’s transplant centers recommend pretransplant dental evaluation and 
treatment of infectious dental foci before LT to prevent sepsis and bacteremia of oral origin 
(9,10,18).  Their guidelines rely mostly on empirical knowledge and can differ greatly among 
transplant centers and countries (17,144).  No uniform guidelines thus exist for the dental 
management of LT candidates.  Still, the general consensus is that eliminating active and 
chronic sources of infection from the oral cavity is essential before LT (7-9).  Sometimes full-
mouth, total extractions are advisable if the patient has advanced periodontal disease and 
shows no interest in oral self-care (7).  The LT candidate should always have his or her oral 
hygiene reinforced with proper home-care instructions.  Current guidelines at HUCH are in 
Table 10. 
 
Post-transplant dental treatment 
 
Infections 
All dental treatment should be avoided until 6 months after transplantation.  
Immunosuppression is strongest during the first months, so patients are extremely prone to 
bacterial, viral, and fungal infections despite prophylaxis to prevent infectious complications.  
Opportunistic oral infections by C.albicans are common at this time, and HSV1 may also 
reactivate and manifest as painful and slow-healing oral ulcers (9).  Removal of plaque 
deposits by toothbrushing is extremely important, and chlorhexidine mouth rinses may be 
beneficial in lessening bacterial inflammation of the oral cavity (145).  Tooth brushing should 
be done carefully because, if the gums are inflamed due to poor oral hygiene, too vigorous 
brushing may result in bacteremia (146).  A hospital dentistry department must be consulted 
if any severe dental problems emerge during the first 6 months, and only emergency dental 
care should be given at this time (9). 
 
After 6 to 12 months the graft should be stabilized, and the patient’s dental care be provided 
by his/her own dentist.  Dental treatment in LT recipients does not differ to any great extent 
from that of the normal population.  Since oral diseases are caused by oral pathogens, plaque 
control is most important to avoid oral and dental diseases and to prevent possible infectious 
complications. A recent study of pediatric LT recipients revealed a need to improve 
utilization of preventive dental care for these patients (147).  Consultation with the patient’s 
physician concerning possible drug interactions is necessary to avoid too low/too high 
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concentrations of immunosuppressive medications (148).  Referral to a special dental unit of 
a hospital is recommended in complicated cases.  Regular oral examinations are essential 
every 6 months to detect early signs of infection of teeth or the oral mucosa.  Even edentulous 
patients are in need of regular dental visits in order to treat possible precancerous or other 
OMLs.  Removable dentures need to be checked regularly for their fit, and possible 
candidosis requires treatment.  Otherwise, patients can receive normal dental care, even 
implants, if the patient’s medical condition is stable, and jaw bone structure is sufficiently 
strong (149).  Effective oral hygiene habits are still the cornerstone of a healthy oral cavity. 
 
Antibiotic prophylaxis 
Invasive dental treatments such as periodontal and restorative treatments in particular are 
associated with some bleeding; in order to avoid infection’s spreading from the oral source, 
antibiotic prophylaxis is recommended for high-risk, immunocompromised LT recipients 
(142,150).  Recommendations follow the guidelines for the prevention of infectious 
endocarditis by the American Heart Association.  The issue of antibiotic prophylaxis is 
controversial, however, and the benefits of antibiotic use should always outweigh the risks 
(151,152).  A current recommendation includes 2 g amoxicillin, or 600 mg clindamycin for 
patients with penicillin allergy, given one hour before dental treatment.   
 
Drug-induced gingival overgrowth (DIGO) 
Drug-induced gingival overgrowth (DIGO) is commonly associated with CsA (153,154);  
simultaneous use of calcium-channel blockers increases its prevalence (34,155).  DIGO can 
be very unpleasant for the patient, and the treatment often involves surgical removal.  Proper 
oral hygiene and periodontal treatment may lower the risk for DIGO (156), but replacing CsA 
with TAC or changing calcium channel-blocker to another antihypertensive may reverse this 
condition (157,158).   
 
Several other oral mucosal lesions afflict LT recipients.  These include OLP, stomatitis, 
fissured tongue, candidosis, leukoplakia, and oral cancer; maxillofacial tumors also occur 
(13,14,159-161).  Corticosteroids lead to increased prevalence of candidosis and more bone 
loss (15), but some of these conditions may have existed even before LT, so it is difficult to 
point out which of these specifically relate to immunosuppressive medications.  Several 
medications may be xerogenic, and xerostomia has been frequently evident in LT recipients 
(9,159,162). 
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AIMS OF THE STUDY 
 
This study focuses on the association between oral conditions and systemic diseases in 
patients receiving a LT.  Since the relationship is bidirectional, we first aimed to study how 
liver disease affects oral health.  Further, the aim was to study how oral health status may 
affect liver disease or LT outcome.  In addition, a further aim was to investigate how the 
immunosuppression which is a direct consequence of the LT may affect these patients’ oral 
health.  The main hypotheses of the study were that treatment of oral infections before LT is 
beneficial for LT prognosis, and, in addition that life-long immunosuppression necessitated 
by LT affects oral health. 
 
 
The specific aims were to investigate: 
 
1. How liver disease etiology or severity affects oral health (Study I).  
2. How dental infections affect the progression of liver cirrhosis (Study II). 
3. What effect pretransplant dental treatment has on the development of systemic infections 
after LT  (Study III). 
4. How immunosuppression affects oral health of LT recipients in comparison to a control 
population  (Study IV).   
5. How immunosuppression affects specifically oral mucosal health of the LT recipients 
when compared with the control population  (Study V).   
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PATIENTS AND METHODS 
 
This study was conducted at the Institute of Dentistry, University of Helsinki, and at the 
Department of Oral and Maxillofacial Diseases and the Transplant and Liver Surgery Clinic, 
Helsinki University Central Hospital (HUCH), Helsinki, Finland.  The study had the approval 
of the HUCH Research Committee, and Studies IV and V had the ethical approval 
(192/13/03/02/2008, 16.8.2008) of the ethics committee of the Helsinki and Uusimaa 
Hospital district.  Permission for the Health 2000 Health Examination Survey in Finland was 
given by the ethics committees of the University Hospital Region of Helsinki and 
Surroundings and the National Public Health Institute.  Each of the patients as well as all the 
Health 2000 Health Examination Survey participants signed an informed consent form which 
was available in both Finnish and Swedish.   
 
Patients 
 
Features of the study design and patient characteristics are presented in Tables 8 and 9 and in 
Figure 4.  The study population comprised all 263 adult recipients of a LT between 2000 and 
2006 at the Transplant and Liver Surgery Clinic, HUCH, Helsinki, Finland.  The follow-up of 
these patients also took place in the same hospital.   
 
Of the study patients, 212 (80.6%) (all chronic liver disease) had dental examinations and 
treatment prior to the LT.  In this examination, oral health status was evaluated and need for 
dental extraction served as the dependent variable (outcome) to study the impact of the 
different liver pathologies (by etiology) and severity (MELD) on oral health status.  Etiology 
groups included PSC, PBC, alcohol cirrhosis, cryptogenic cirrhosis, other cirrhosis, liver 
tumors, and other chronic liver diseases (Study I). 
 
Of the chronic patients, 116 (54.7%) had end-stage liver cirrhosis. Their tooth extractions 
were used as evidence of the progression of liver cirrhosis as seen in MELD score change 
during one year before dental examination.  Episodes of spontaneous bacterial peritonitis 
(SBP) cases were compared between two groups formed by the median number of tooth 
extractions during pretransplant dental evaluation (Study II). 
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Of the study patients, (51) 19.4% had LT due to acute or subacute liver failure.  They were 
subsequently stratified by whether they had had pretransplant dental treatment (n=16), or 
none (n=35).  The occurrence of systemic infectious complications and their related 
microbiota after LT was assessed from the Finnish LT Registry (Study III). 
 
Figure 4.  Patient profile among different studies.   
 
 
                                                      
                        
 
 
 
 
 
                                                                                                           Exclusion:  Children under 15 
                            Exclusion:                                                              (n=36) 
                            no pretransplant dental 
                            evaluation  
                            (n=7) 
                                           
                                        
                                          
 
               
 
 
 
 
 
 
 
                                                
                                              
 
                                                       
                                                      Post-transplant oral examination during 
                                                      2008 and 2011 with minimum follow-up  
                                                      of 2 years (84): 
                                              
 
 
 
 
 
 
 
 
 
 
 
 
All liver transplantations 
during  2000 and 2006 
in Finland 
(N=306) 
 
Chronic liver 
disease patients 
(212) 
Study I 
Acute liver failure 
patients 
(51) 
Study III 
Cirrhotic patients 
(116) 
Study II 
 
Chronic LT 
recipients 
(64) 
Studies IV-V 
Acute LT  
recipients 
(20) 
Studies IV-V 
64 chronic and 7 acute 
LT recipients with both 
pre- and post-transplant 
oral health examinations 
(71) 
Unpublished data 
Study population,  
adult LT recipients 
(263) 
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Table 8.  Features of study design and patient characteristics. 
 
 
 
AIH, autoimmune hepatitis; ALCI, alcohol cirrhosis; CRCI, cryptogenic cirrhosis; OTCI, other 
cirrhosis; OTHER, other chronic liver diseases; PBC, primary biliary cirrhosis; PSC, primary 
sclerosing cholangitis 
* including autoimmune hepatitis and viral hepatitis 
¶ including Budd-Chiari and metabolic liver diseases 
§ Health 2000 Health Examination Survey in Finland; matched for age, gender, and residence area 
 
 
 
 
 
Study number 
 
I II III IV V 
Number of patients 212 116 51 84 84 
Inclusion Chronic pre- 
transplant 
patients 
Cirrhotic 
pretransplant 
patients 
Acute pre- 
transplant 
patients 
Post- 
transplant 
patients 
Post- 
transplant 
patients 
Study design Retrospective, 
cross-sectional 
Retrospective, 
cross-sectional 
Retrospective, 
cross-sectional 
Prospective, 
cross-sectional, 
case-control 
Prospective, 
cross-sectional, 
case-control 
Control group No No No Yes § Yes§ 
Data collection Patient 
records 
Patient 
records, 
LT Registry 
 
Patient 
records,  
LT Registry 
Patient records, 
protocol oral 
examination, 
questionnaire 
Patient records, 
protocol oral 
examination, 
questionnaire 
Age at LT,  
median (range) 
51 (15-74) 49 (39-66) 48 (19-68) 55 (25-71) 55 (25-71) 
Gender, men % 57 54 35 61 61 
LT diagnosis, all % 
Chronic 
 PBC 
 PSC              
 ALCI 
 CRCI 
 OTCI* 
 OTHER ¶ 
Acute 
 Unknown  
 Drug-related 
 AIH 
 Acute Budd-Chiari 
 Other  
Liver tumors 
 
 
89 
15 
25 
17 
  7 
16 
  9 
 
 
 
 
 
 
11 
 
100 
27 
 
32 
13 
28 
 
 
 
 
 
 
100 
  59 
  18 
  12 
    8 
    3 
 
 
71 
  7 
27 
14 
  7 
11  
  5 
24 
 
 
 
 
 
  5 
 
71 
  7 
27 
14 
  7 
11 
  5 
24 
 
 
 
 
 
  5 
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A subset population of 84 eligible LT recipients were recruited for a clinical oral health 
examination with a minimum follow-up of 2 years (median follow-up 6 years, range 2-11) 
after LT.  A questionnaire (Appendix) allowed assessment of dry-mouth-related symptoms, 
Candida was cultivated and salivary flow rates were measured.  Complete oral health status 
according to a fixed protocol and subjective oral symptoms were evaluated and compared 
with those of a matched control group of 252 from a national health survey.  Groups were 
formed by LT etiology or by difference in immunosuppression (Studies IV-V).          
 
 
 
Table 9.  Oral health status among studies and in controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study I Study II Study III Study IV Study V Controls 
Number of teeth, 
  mean (SD) 
23 (8) 22 (9) 21 (11) 22 (9) 22 (9) 20 (10) 
Number of carious 
  teeth, mean (SD) 
2 (3)   1.1 (1.4) 1.1 (1.4) 0.5 (0.9) 
Number of     extractions,   
mean (SD) 
3 (4) 4 (4) 4 (7) 0 (1) 0 (1)  
Percentage of oral  
  mucosal lesions 
 
19   43 43 15 
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Oral examination 
 
Pretransplant oral health status (Studies I-III) 
In LT candidates PTG had been performed before a clinical oral examination which included 
assessment of oral infectious foci. A radiologist’s written statement was available for 
diagnosis.  Number of teeth was calculated from PTG.  Oral mucosal status was recorded, 
number of carious teeth (teeth to be filled) was assessed, and the quality of possible dentures 
was recorded as well.  Differing dental infectious foci were reported separately in Study I; 
they included all non-restorable teeth as presented in Table 10 according to HUCH guidelines 
for the dental management of LT candidates before their acceptance on a waiting list for LT.   
 
Table 10.  Current guidelines for LT candidates at HUCH. 
 
Oral source of infection Procedure 
Cysts, abscesses of the jaws Surgical operation  
Infectious dental foci:  
   Periapical osteitis/apical periodontitis  
   Advanced periodontitis; ≥6 mm periodontal 
   probing depth / severe alveolar bone loss 
 
 
   Vertical, bony pockets extraction of teeth 
   Deep carious lesions reaching the pulp 
   (devital teeth) 
 
 
   Root remnants  
   Wisdom teeth with pericoronitis  
Carious lesions (vital teeth) Temporary or permanent fillings 
Dental calculus Removal, scaling and root planing 
Plaque deposits Removal and guidance in oral self-care 
Oral mucosal lesions Treatment of candidosis and other oral mucosal   
pathologies 
 
Dry mouth Information, recommendation of saliva substitutes 
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A liver surgeon was the consultant, regarding the current status of the patient, drug selection 
and dosage, and need for possible replacement therapy to prevent any bleeding associated 
with the dental procedures.  Tooth extractions were done in a hospital operating room with 
necessary antibiotic prophylaxis to prevent systemic infections.  Restorative treatments were 
done by placement of either temporary or permanent fillings into teeth, and dental calculus 
was removed.  Periodontal treatments were often carried out in an operating room, in case of 
bleeding.  Oral hygiene was emphasized to the patients waiting for a LT.  Some patients may 
have been so ill that dental treatment had to be postponed due to rapidly progressing liver 
failure without the possibility of an oral examination. 
 
Post-transplant oral health status (Studies IV-V) 
A new PTG was performed to discover any signs of infection in the jaws.  Two experienced 
hospital dentists examined patients during antibiotic prophylaxis according to a standard 
protocol.  Oral health status was recorded, including oral mucosal status, periodontal status, 
and cariological status as well as assessment of occlusion and possible temporomandibular 
joint dysfunction.  Saliva secretion was measured for both unstimulated and stimulated whole 
saliva and mucosal samples taken for possible Candida infection.  Quality of possible 
dentures was recorded.  In addition to oral health data, background demographic and clinical 
data for all studies included age, gender, time of LT, etiology for LT (liver disease diagnosis), 
waiting time for LT, other diseases, medications, and MELD score.  The data were assessed 
from patient medical and dental records, radiographs, the Finnish LT registry, and HUCH 
laboratory database. 
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Questionnaire 
 
For Studies IV-V, LT recipients filled in a questionnaire before the clinical oral examination 
(Appendix).  A similar questionnaire has been used in our clinic in several previous and also 
in ongoing studies (163).  The questionnaire was available in the two official languages of 
Finland: Finnish and Swedish.  It inquired about educational level, working status, last dental 
visit, smoking, alcohol use, and self-assessment of oral health, and several questions were 
aimed at assessment of dry-mouth-related oral symptoms.   
 
Control population 
 
Control data for Studies IV and V came from the Health 2000 Health Examination Survey in 
Finland in which a total of 6335 individuals participated both in a clinical oral health 
examination and in a home interview during 2000-2001 (164).  This nationwide survey 
sought information on the most important public national health problems, their causes, and 
treatment, as well as on the population’s functional capacity and working capacity (165).  
Liver disease was an exclusion criterion in control-subject selection, but not other systemic 
diseases, like cardiovascular disease and diabetes.  Three control subjects for each LT 
recipient were matched with respect to age, gender, and area of residence, and the matching 
was done separately for chronic and acute LT recipients.   
 
The oral examination included PTG and thorough examination of the oral mucosa, teeth, and 
gingival tissue (164).  The oral examination was performed in a similar manner as for the LT 
recipients, except that no salivary flow was measured and no Candida cultivation took place.  
The questionnaire for the controls covered educational level, working status, dysphagia, 
burning mouth, and dysgeusia, as well as questions on self-assessment of one’s own oral 
health.  Information regarding smoking and alcohol use of the controls came either from the 
questionnaire or home interiew. 
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Statistical analysis 
 
The statistical software was PASW (IBM Co., Armonk, NY, USA) versions 17.0 and 18.0.  
In general, the Chi-Square (Fischer’s exact test, two-tailed) test served for categorical 
variables and the Mann-Whitney U-test for continuous variables.  All CIs were calculated at 
the 95% level, and P-values <0.05 were considered significant. 
 
One-way ANOVA served to analyze differences in means between the liver disease etiology 
groups.  Student’s t-test or the non-parametric Mann-Whitney U-test served for study of 
statistical associations between liver disease etiology groups and MELD score groups in 
relation to oral health.  Uni- and multivariate logistic regression analysis was performed to 
study risk factors associated with worse oral health (Study I). 
 
Associations between number of days from diagnosis of liver disease to LT and number of 
tooth extractions were tested by uni- and multivariate linear regression.  Correlations between 
number of tooth extractions (median tooth extractions) and change in MELD score during the 
preceding year before LT were evaluated by Spearman test (Study II).  Infection risk was 
assessed by two methods: by incidence rates, which takes into account multiple infections in 
the same patient and by Cox regression analysis, which allows for multivariate analysis. 
Multivariate analysis included both pre- and post-transplant variables such as age, gender, 
etiology of acute liver failure, waiting time for LT, MELD score, and immunosuppression.  
The Kaplan–Meier method with the log-rank test served for survival analysis to compare 
infection incidences between groups (Study III). 
 
Multivariable binary logistic regression analysis (backward Wald) allowed assessment of  
possible risk factors for the subjective oral symptoms in LT recipients.    Variables entered 
into the model were:  age, gender, follow-up time, diabetes, current alcohol use, current 
smoking, number of medications, central nervous system medications, cardiovascular 
medications, pulmonary medications, working status, and removable dentures (Study IV).  
Logistic regression analysis involved risk factors for OML both in LT recipients and in 
controls.  Variables entered into the same model:  case/control, age, dysphagia, presence of 
removable dentures, number of teeth, alcohol use, current smoking, and total number of daily 
medications and cardiovascular medications (Study V).   
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RESULTS  
 
Pretransplant dental evaluation of chronic LT candidates (Study I) 
 
Among 212 chronic LT candidates, mean number of teeth was 23 (including 11 edentulous 
patients).  The 31 PBC patients had significantly fewer teeth than did the 54 PSC patients (20 
vs. 26, P<0.005); 11% of the patients had removable dentures.  Of the CLD patients, 133 
(63%) required tooth extractions, and 14 (11%) of them needed hospital treatment for 
complications associated with tooth extraction.  10 had episodes of excessive bleeding, and 4 
had fever, and these complications occurred only among the cirrhotic patients: ones with 
alcohol cirrhosis, PBC, or other cirrhosis.  On average, 3 teeth each were extracted, among all 
patients.  The highest number of tooth extractions had occurred in alcohol cirrhosis patients, a 
difference significant when compared to PSC patients (6  vs. 3, P<0.005).  LT candidates 
with a higher MELD score (11-18) associated significantly with older age, fewer teeth, and 
more tooth extractions when compared with those patients with a lower MELD score (1-
10),  as shown below.  
 
Table 11.  Dental health status of CLD patients by MELD group. 
 
 
 
 
 
 
 
 
 
 
 
 
*   P<0.05, CI: 0.4-8.1 
¶   P<0.005, CI: -6.7-(-)1.4 between middle and lower MELD groups 
§   P<0.001, CI: 1.6-4.2 
               ** P<0.05, CI: 0.4-2.6 between upper and lower MELD groups 
 
 
By univariate analysis, a higher MELD score (OR=0.6, CI: 0.5-1.0, P<0.05) and certain 
etiologies such as alcohol cirrhosis (OR=0.2, CI: 0.0-0.5, P<0.005) correlated with need for 
tooth extractions but after adjusting for several confounders, age remained the only 
significant factor for tooth extractions (OR=1.0, CI: 0.9-1.0, P<0.005). 
 
 MELD 1-10 
n=80 
MELD 11-18 
n=74 
MELD 19-40 
n=58 
Age, mean (SD) 47 (12) * 51 (12)  50 (12) 
Number of teeth, mean (SD) 25 (7)   ¶ 21 (10) 23 (7) 
Number of extractions,  
   mean (SD) 
  2 (3)   §   5 (5)   3 (4)  ** 
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Association between dental infections and clinical course of chronic liver 
disease (Study II)  
 
In univariate linear regression analysis, multiple tooth extractions in liver cirrhosis patients 
were associated with worsening of liver cirrhosis as indicated by a shorter duration from 
diagnosis of liver disease to need for LT (P<0.05).  After adjusting for various confounders, 
as seen in Table 12, the association between multiple dental infections and progression of 
liver cirrhosis remained significant (P<0.05).  Liver cirrhosis patients with 6 or more tooth 
extractions (= dental infectious foci) had their LT approximately 3 months earlier than those 
patients who had less than 5 extractions.   
  
Among a subgroup of patients residing within the transplant center’s hospital district (n=38) 
and with accurate laboratory follow-up data, the MELD score increased by roughly 4 units on 
average during the year preceding the dental examination, and it correlated with the number 
of tooth extractions (r=0.43, P<0.05).  Among 38 patients, 10 had 13 episodes of SBP.   
Streptococcus viridans occurred only among patients with multiple tooth extractions.   
 
Table 12.  Association between number of tooth extractions and time in days from diagnosis 
to LT among patients with liver cirrhosis. 
 
 Univariate Multivariate 
 Beta 95% CI P Beta 95% CI Significance 
 
Tooth extractions 
 
-147 
 
-269-(-25.5) 
 
0.02 
 
-96.2 
 
-196-(-5.80) 
 
<0.05 
Age 30.8 -22.8-84.5 0.24 38.0 -12.3-88.2 Ns 
Alcohol cirrhosis -2733 -3819-(-1647) <0.001 -1872 -3443-(-302) <0.05 
MELD score -3.73 -75.6-68.1 0.92 47.2 -26.7-121 Ns 
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Oral infections and post-transplant infectious complications among acute 
or subacute LT recipients (Study III) 
 
Among acute LT recipients, lack of dental treatment before LT elevated their risk for post-
transplant infectious complications by 8-fold in the multivariate Cox regression analysis 
(OR=8.54, 95%CI:1.82–40.1, P<0.05), taking into account several pre- and post-transplant 
factors: age, gender, etiology of acute liver failure, waiting time for LT, MELD score, and 
level of immunosuppression.  Both early (<6 months) and late (>6 months) post-transplant 
infections occurred significantly more often in the group without dental treatment.  Nine 
cases of septic infections occurred in the group without dental treatment but only one septic 
episode in the group with dental treatment.  Pathogens occurring in the groups are shown 
below. 
 
Table 13.  Pathogens isolated from the septic complications after LT by group. 
 
 
 
 
 
  
 No dental 
treatment 
n=16 
Dental  
treatment 
n=35 
Klebsiella spp. 3  
Escherichia coli 2  
Staphylococcus epidermidis 1 1  
Pseudomonas aeruginosa (tobramycin resistant) 1  
Enterococcus faecalis 1  
Candida albicans 1  
   
Total number of septic episodes 9 1  
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The cumulative infection incidence (number of patients with at least one infection episode) 
reached over 80% at 9 months post-transplant in the group without dental treatment, but 
remained under 30% in the group with pretransplant dental treatment as shown in Figure 5. 
This difference between the groups emerged mainly during the first 3 months after 
transplantation. 
 
 
Figure 5.  Cumulative infection incidence. 
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Effect of immunosuppression on oral health in LT recipients compared to a  
control population (Study IV) 
 
Median follow-up time after LT was approximately 6 years (range 2-11) among both chronic 
(n=64) and acute (n=20) LT recipients.  Between chronic and acute LT recipients, 
immunosuppressive medication did not differ.  About half of all patients used CsA and the 
other half TAC.  Only 4 chronic LT recipients used mTOR.  Table 14 shows number of 
medications, salivary flow rates, oral health data, as well as subjective oral symptoms and 
other data obtained from the questionnaire in LT recipients and controls.  Of all LT 
recipients, 24% wore removable dentures.   
 
Dysphagia was significantly more common in chronic LT recipients than in controls (23% vs. 
12%, P<0.05).  Neither burning mouth syndrome (BMS) nor dysgeusia was more common in 
LT recipients. 
 
Taking 8 or more different daily medications, including immunosuppression and concomitant 
disease medication, when compared with 4 or fewer, raised risk for xerostomia significantly 
in the chronic LT recipients (P<0.01).  The same trend was evident in acute LT recipients.  
For controls, taking 8 or more daily medications led to significantly increased risk for BMS 
when compared to 4 or fewer  (P<0.05). 
 
Working correlated with xerostomia (OR=0.3, 95%CI: 0.1-0.8, P<0.05).  Risk factors for 
BMS included older age and shorter follow-up after LT (OR=1.1, 95%CI: 1.0-1.2, P<0.05; 
OR=0.5, 95%CI: 0.3-0.9, P<0.01, respectively).  Medications to treat disorders in the central 
nervous system increased risk for dysphagia (OR=2.9, 95%CI: 1.3-6.6, P<0.05) and having 
dentures correlated with dysgeusia (OR=23.4, 95%CI: 1.1-511, P<0.05). 
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Table 14.  Oral health data in LT recipients and controls. 
 
 
NK, not known 
† P<0.001 between LT recipients and their controls  
‡ P<0.01 between chronic and acute LT recipients 
* P<0.005 between LT recipients and their controls  
¶ P<0.05  between LT recipients and their controls 
 
 
 Chronic LT 
recipients 
n=64 
Controls for 
chronic 
n=192 
Acute LT 
recipients 
n=20 
Controls for 
acute 
n=60 
Number of medications, 
  mean (SD) 
 
7 (2) † 2 (2) 6 (2) 2 (2) 
Cardiovascular  
  medications, % 
 
86 † 35 95 † 25 
Unstimulated salivary  
  flow,  ml/min, mean (SD) 
 
0.3 (0.3) ‡ NK 0.6 (0.5) NK 
Stimulated salivary  
  flow, ml/min, mean (SD) 
 
1.7 (1.1) NK 1.8 (0.9) NK 
Reduced unstimulated  
  salivary flow (≤0.1 ml/min), % 
 
31 NK 10 NK 
Reduced stimulated  
  salivary flow (≤0.7 ml/min), % 
 
20 NK 10 NK 
Xerostomia, % 48 NK 42 NK 
Dysphagia, % 23 ¶ 12 5 15 
Burning mouth syndrome, % 19 12 5 23 
Dysgeusia, % 5 8 0 13 
Number of teeth, mean (SD) 21.2 (8.5) 20.5 (9.8) 23.1 (8.5) 19.5 (10.4) 
Number of carious teeth,  
  mean (SD) 
 
1.1 (1.5) * 0.5 (1.0) 0.9 (1.1) ¶ 0.5 (1.1) 
Self-assessment of  
  oral health,  good, % 
 
38 * 61 47 ¶ 65 
Alcohol use, % 38 † 82 20 † 78 
Current smoking, % 14 24 20 30 
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Effect of immunosuppression on oral mucosal health in LT recipients 
compared to control population (Study V)  
  
OMLs were significantly more frequent in LT recipients (43%) than in controls (15%) 
(P<0.001).  Different types of OMLs could have occurred simultaneously in the same patient 
(Table 15).  Precancerous OMLs were twice as common in chronic LT recipients as in 
controls (12.5% vs. 5.7%, Ns).  DIGO was significantly more common in the CsA (29%) 
than in the TAC group (5%) (P<0.01), and simultaneous use of calcium-channel blockers led 
to increased risk when a calcium-channel blocker was added either to CsA (47%) or TAC 
(8%) (P<0.05).  Use of steroids increased the risk for any OML (53%) and for Candida 
(68%) (Ns). 
 
Table 15.  Oral mucosal lesions in LT recipients and in controls  
 
 
 
 
 
 
 
 
 
 
 
NK, not known 
* P<0.001 between LT recipients and their controls 
¶  hairy tongue, atrophic tongue, fissured tongue, geographic tongue 
§  OLP, leukoplakia, erythroplakia, ulcers (excluding frictional keratosis) 
† angular cheilitis, echymoses (bruise), petechiae, fistula, tumor-like structures (e.g. fibromas, 
hemangiomas, mucoceles), and other inflammatory oral mucosal lesions 
 
Risk factors for OMLs were investigated in the same regression model for both the 84 LT 
recipients and  252 controls.  Risk was highest for LT recipients (OR=9.2, 95%CI: 4.5-19.0, 
P<0.001).  Other significant risk factors were number of teeth, current alcohol use, and 
smoking (OR=0.9, 95%CI: 0.9-1.0, P<0.001; OR=2.4, 95%CI: 1.2-5.0, P<0.05; OR=2.0, 
95%CI: 1.0-3.8, P<0.05). 
 Chronic LT 
recipients 
n=64 
Controls 
for chronic 
n=192 
Acute LT 
recipients 
n=20 
Controls 
for acute 
n=60 
Any oral mucosal  
lesion, (%) * 43.8 * 14.1 40.0 16.7 
  DIGO  16.1 * 1.0 20.0 0.0 
  Mucosal hyperplasy 4.7 2.6 10.0 3.3 
  Denture stomatitis 1.6 5.7 10.0 8.3 
  Tongue lesions ¶ 9.4 NK 5.0 NK 
  Precancerous lesions § 12.5 5.7 5.0 10.0 
  Other oral  
  mucosal lesions  † 9.4 9.9 10.0 10.0 
 
Candida infection, % 57 NK 55 NK 
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Comparison of oral health data before and after LT (unpublished data) 
 
Both pre- and post-transplant oral health data were available for 71 LT recipients.  Changes 
in their oral health data are presented in Table 16.  Although the mean number of teeth was 
significantly lower (from 25 to 21 teeth), a significant improvement had occurred in 
prevalence of oral infection foci and caries lesions.  Oral mucosal health seemed also to have 
improved but not significantly. 
 
 
Table 16.  Comparison of pre- and post-transplant oral health data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oral health status Before LT After LT Significance 
Oral mucosal pathologies, % 52  45 Ns 
Number of teeth,  
  mean (SD) 25 (8)  21 (9) P<0.001 
Number of carious teeth, 
  mean (SD) 2 (2)  1 (1) P<0.01 
Infectious dental foci,  
  mean (SD) 3 (3)  0 (0) P<0.001 
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DISCUSSION 
 
Infection risk 
 
In the group of ALF patients who had no dental treatment before LT, risk for infectious post-
transplant complications was higher, and this significantly elevated risk emerged even after 
adjustment for various confounding factors.  Two fatal septic complications occurred only in 
the group lacking dental treatment.  Most infection episodes occurred very early, within the 
first 3 months post-transplant when the level of immunosuppression was highest.  These 
findings stress the importance of eliminating – whenever possible – all potential sources of 
infectious oral and dental foci before LT (4), taking into consideration the patient’s medical 
condition.    
 
Oral bacteria were not, in this study, cultivated from mouth samples, but two possible oral-
derived microbes were isolated in the systemic infections:  E. faecalis and C.albicans.  LT 
candidates generally had poor oral health before transplantation, and it may be assumed that 
the group that had no dental treatment may have had several untreated dental infections. 
Inflammation caused by gingivitis or periodontitis possibly led to the increased levels of 
proinflammatory cytokines, ones such as TNF-α, IL-1, and MMPs, which then triggered such 
systemic infections. 
 
SBP is a very serious complication with high mortality in cirrhotic patients, and these 
infections may be caused by various pathogens.  Different viridans group streptococci such as 
S.mitis, S.mutans, S. salivarius, and S. oralis, have been reported in SBP episodes among 
CLD patients (48), and all these microbes can occur in the oral cavity.  Our results showed 
that S. viridans cases emerged only among those LT patients who had undergone multiple 
tooth extractions and therefore had worse dental health.  Although oral pathogens were not 
cultivated in this retrospective study, we can still speculate that since S.viridans is abundant 
in the oral cavity, those peritonitis cases associated with S.viridans may have originated from 
dental infections.  Poor oral hygiene and carious lesions are associated with viridans group 
streptococci, of which, S.mutans is the caries pathogen.  Even among healthy individuals, if 
they have poor oral hygiene and untreated dental infections, they may have S. mutans  
spreading through inflamed gums into their general circulatory system and leading to 
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bacteremia and sepsis.  The consequences of S. viridans-derived bacteremia in patients with 
immune deficiency can, however, be fatal (166).  In infective endocarditis, S. viridans is the 
most common causative pathogen, with especially the serotype k S. mutans highly virulent in 
systemic diseases (167). 
 
Interest has increased in the relationship between periodontal disease and liver disease.  A 
recent study showed periodontal disease to have an effect on lipid levels and therefore to 
impact the progression of liver disease (115).  Similar findings came from another study that 
found effects of inflammatory mechanisms of proatherogenic pathogens upon lipid 
metabolism in an animal model (168).  In yet another study, HCC patients with chronic 
periodontitis showed a more severe form of HCC (116). We assume that the circulating 
periodontal and other oral cytokines in our cirrhotic patients added to the overall 
inflammation in the body, triggering the progression of chronic liver disease.  This is a novel 
finding, since the possibility of oral-derived bacteremia in the course of chronic liver disease 
has been poorly studied, but prospective studies are necessary to confirm the causative 
relationship between dental infections and CLD progression. 
 
Oral health data 
 
LT candidates experienced frequent dental and oral infections in general but the differing 
etiologies of CLD affected their oral health differently. Our results are in line with others’ 
that have shown generally poor oral health among LT candidates (119), but our study is the 
first to report on oral health status between etiology groups and especially according to 
MELD score.  The MELD score of PBC and alcohol cirrhosis patients was considerably 
higher than that of PSC patients, and seemed to associate with worse oral health.  PBC 
patients had the least number of teeth, and the alcohol cirrhosis patients had the most tooth 
extractions in comparison with PSC patients. 
  
Not all PSC patients had developed end-stage CLD, and their indications for LT included 
recurrent cholangitis episodes or progressive changes in the bile ducts that could develop into 
cholangiocarcinoma.  The better general health, and younger age among PSC patients most 
likely also affected their oral health status as seen in their higher number of teeth.  PBC and 
alcohol cirrhosis patients, on the other hand, often were in end-stage liver insufficiency 
during pre-transplant dental evaluation.  Smoking and alcohol are significant risk factors for 
60 
 
periodontitis (169,170), and the alcohol cirrhosis patients often also smoked or had been 
heavy smokers.  Ours is in agreement with a previous study that showed differences in oral 
health between alcohol cirrhosis or other cirrhotic patients and healthy controls (171).  
Alcohol cirrhosis patients were also presumed to neglect their oral health care, which may 
have led to the full-mouth extractions evident among several of our alcohol cirrhosis patients.  
These risk factors as well as basic differences in the etiologies of liver disease and also CLD 
severity  may have affected oral health between CLD groups. 
 
Because liver cirrhosis is associated with high risk for bleeding and infections, dental 
treatments in these patients also proved to be risky according to our own investigation.  Some 
of the bleeding complications were still occurring several days post-operatively and required 
hospital treatment.  The cases of fever needed strong iv-antibiotics.  These complications 
occurred only in those patients with end-stage CLD, so a worse general health condition 
among cirrhotic patients was also reflected by their dental-treatment history.  Although 
studies in this field report bleeding complications during dental procedures among CLD 
patients (102,109,111), one recent study found no episodes of postoperative bleeding in CLD 
patients following invasive dental procedures (172).  The patients in that study differed with 
ours, however.  That study by Hong et al. included CLD patients who had no end-stage liver 
insufficiency and had a mean INR of less than 2; they needed no replacement therapy, 
whereas we frequently used replacement therapy for our end-stage CLD patients.  Patients 
with CLD should be reminded of the importance of regular dental visits and good oral 
hygiene during the course of their liver disease and well before planned LT.  This may result 
in fewer tooth extractions and possibly also lead to a more favorable outcome regarding high-
risk dental treatments (173).  This in turn could also contribute to less expense in treating 
these immunocompromised patients for complications that may develop and may require 
specialized health care.   
 
 
Oral findings in LT compared to those in controls 
 
LT recipients’ oral health data was compared to that of a general Finnish population by our 
forming control groups matched with the LT recipients by age, gender, and residence area.  
The LT recipients were followed on average for 6 years after transplantation.  Several 
significant differences emerged in oral health, especially between the chronic LT patients and 
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controls.  Those chronic LT patients presenting with significantly more caries also suffered 
from dysphagia significantly more often.   
 
The largest difference in oral health data between LT patients and controls was in the 
frequency of OMLs.  In Study V, these occurred in 43% of the LT recipients and were most 
likely attributable to immunosuppressive medications, since DIGO was the single most 
common type of lesion.  Our results support previous research in that respect (154-159).  
Compared to a study by Diaz-Ortiz et al (159), fissured tongue was less common among our 
patients, a  difference perhaps explained by differing etiologies in LT.  Viral hepatitis is not a 
common indication for LT in our country, in contrast to the situation in many other countries. 
 
Our chronic LT patients showed a marked risk for precancerous lesions such as leukoplakia.  
Alcohol use and smoking are common risk factors for such potentially malignant oral lesions 
(75).  Here, these risks correlated with OMLs, but it is noteworthy that LT patients used 
alcohol and smoked far less than did the population controls.  We therefore assume that the 
effect of immunosuppressive medications on potentially malignant lesions remains strong. 
Transplant recipients in general experience a roughly 2 to 4-fold elevated risk for de-novo 
cancers (174).  Especially skin cancers have been reported in this population (175).  In 
addition, persistent infection with oncogenic viruses – those such as Kaposi sarcoma EBV, 
high-risk HPVs, and EBV in general - are associated with an up to 100-fold increased risk for 
malignancies (176). 
 
Assessment of their own oral health was also investigated between the LT patients and 
controls.  The chronic LT patients felt that their oral health was significantly less good.  An 
earlier study from our own center investigating health-related quality of life and employment 
status in LT recipients (1) included most of the same patients as in the present study.  
Younger patients often returned to work in less than 6 months after LT.  Being active and 
younger may therefore also reflect the way that these patients perceive their oral health status.  
Missing teeth and impaired chewing function could also account for worse perception of oral 
health.  A large number of teeth were extracted before LT, and prosthetic rehabilitation was 
not always done.  Only one patient had a dental implant replacing a missing molar; most 
patients’ molars were not replaced if they still retained premolars. 
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Medications 
 
LT recipients used on average 7 different daily medications, a difference highly significant 
with respect to the control population’s.  In addition to immunosuppressive medications, 
among which CsA and TAC were used equally between the patient groups, were other 
medications, most commonly cardiovascular ones.  CNIs and corticosteroids elevate the risk 
for hypertension.  This in turn can lead to cardiovascular disease, one of the leading causes of 
late mortality among LT recipients (174).  For blood pressure, drugs of choice are selective ß-
blockers, diuretics, ACE-inhibitors, calcium channel blockers, and other cardiovascular 
medications.  Cardiovascular medications are xerogenic, and diuretics in particular reduce 
salivary flow (177).  
 
Indeed, the high number of daily medications may have caused hyposalivation and 
xerostomia which led to increased susceptibility to caries and dry-mouth-related symptoms 
(178).  The increasing number of medications seemed to be linked to increases in all the dry-
mouth-related symptoms, both among patients and controls; although significant differences 
between  number of drugs emerged only in relation to xerostomia in the chronic LT patients, 
whereas burning mouth syndrome was frequent among the control population. 
 
When our immunosuppressant groups among the LT patients were compared in relation to 
OML,  DIGO was the single most common type of OML in LT recipients and to no one’s 
surprise, CsA and concomitant use of calcium-channel blocker increased its prevalence 
significantly over that of TAC supporting previous research (34,153-155).  Systemic 
corticosteroid use promoted the prevalence of all OMLs.  Risk for oral candidosis in 
particular increased considerably, with more than half of all LT patients being positive for 
Candida.  In addition to steroids and other immunosuppressants, another risk factor that may 
have added to risk for Candida may have been the dentures often showing a need for repair.  
The porous surface of a denture is an ideal habitat for oral microbes.  Our finding agrees  
with findings also of a high prevalence of candidosis among transplant populations (52,179). 
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Dry mouth 
 
Among all LT patients, xerostomia was highly prevalent.  Dysphagia, a term which might 
describe the feeling of dry mouth even better, was a significantly more frequent complaint 
among chronic LT patients than among population-based controls.  Similar findings with 
respect to dry mouth were found by Guggenheimer and coworkers but their study included 
LT candidates (11). Patients responded that dry mouth was felt mainly at night-time, 
unsurprisingly, because salivary secretion follows circadian rhythms (41).  A subjective 
feeling of dry mouth in LT patients did not always correlate with objectively measured 
hyposalivation, since only 46% of the patients diagnosed with hyposalivation reported 
xerostomia.  Similar findings have also been reported (180). 
 
Our  chronic LT patients reported all dry-mouth-related symptoms more frequently than did 
the acute LT patients, who in turn showed even fewer symptoms than did the population-
based controls.  Immunological variations by liver disease etiology may explain these 
differences.  Chronic LT recipients included many with autoimmune liver disease such as 
autoimmune hepatitis or PBC, which may share similar characteristics with Sjögren’s 
syndrome.  These patients are known to suffer from sicca syndrome (99,132,181).  One-third 
of the chronic LT patients also had diabetes, which predisposes to reduced salivary flow (83).  
PBC patients also commonly used cardiovascular and psychiatric medications, known to 
affect salivary flow (81).  Therefore, immunological differences, other concomitant diseases, 
and medications affecting salivary flow may explain why the chronic LT patients had 
significantly lower salivary flow rates than did the acute patients. 
 
Hyposalivation is a considerable risk factor for all oral and dental diseases, so the 
significantly lower unstimulated salivary flow may be the cause of the higher incidence of 
caries in the chronic than in the acute patients or in controls.  Dental caries progresses rapidly 
in a dry mouth; especially root caries is a challenge dentists face when treating patients who 
retain their teeth until old age (182,183).  In addition, dry mouth is very unpleasant for the 
patient, causing difficulties in speaking, eating, tasting, or wearing removable dentures, and 
the possible oral mucosal lesions can be extremely painful in a dry mouth.  Dry mouth is a 
real challenge in immunocompromised LT patients taking several medications.  Regular 
dental appointments are extremely important for them since undetected oral infections can 
cause systemic complications.  Good oral hygiene is most important in minimizing risk for 
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oral-derived inflammation that could compromise general health.  Edentulous patients also 
need reminders of regular oral examinations since potentially malignant lesions are usually 
more common in denture wearers and dentures also need regular checking for fit and 
condition.  All clinicians treating such patients should encourage them to quit smoking and 
use alcohol moderately; these factors, together with xerogenic medications, pose a real threat 
of oral cancer as well. 
 
Does liver transplantation worsen or improve oral health? 
 
Our oral health data were available both before and after LT in a subgroup of 71 patients.  A 
large number of oral infection foci were prevalent before LT, but after LT only a few 
sporadic cases included severe dental infections that resulted in tooth extractions.  Although 
LT recipients are at risk for caries, after LT ours showed significantly fewer caries.  Their 
oral mucosal status also seemed to improve slightly after LT, although a high prevalence of 
drug-induced oral mucosal lesions occurred.  Those lesions that were associated with the 
underlying liver disease, for instance, petechias present in the oral mucosa of cirrhotic 
patients had disappeared due to their now-functioning liver.  It is noteworthy that the patients 
were examined differently in Study I than in Studies IV and V; the latter studies included a 
fixed protocol.  We can therefore assume that some OMLs may have been overlooked during 
pretransplant dental evaluation, and the true prevalence of OMLs before LT may have been 
even greater.  Overall oral health status, indeed, thus seemed to improve due to LT. 
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KEY FINDINGS AND CONCLUSIONS 
 
Good oral and dental health is of utmost important for LT patients both in the pre- and the 
post-transplant stages.  The following conclusions can be drawn from the present series of 
studies: 
 
1. Chronic liver disease affected oral health differently depending on the underlying etiology 
and severity of the disease.  PBC patients had on average 20 teeth in comparison to PSC 
patients’ mean number of 26 teeth.  Alcohol cirrhosis patients had the most teeth extracted, 
and their dental treatments were often linked with serious complications such as bleeding 
problems and post-operative infections.  More severe liver disease condition seemed to 
correlate with worse oral health status (Study I). 
 
2. Dental infections were associated with the progression of chronic liver disease.  Cirrhotic 
patients with the most teeth extracted had a shorter time from their diagnosis of liver disease 
to their need for LT (Study II). 
 
3. In the acute LT recipients, treatment of dental infections before LT was associated with 
fewer systemic infections after the operation.  For those patients who lacked pre-transplant 
dental treatment, risk for post-transplant systemic infections was 8-fold higher.  (Study III). 
 
4. Compared to population controls, chronic LT recipients had twice as many caries lesions 
and reported almost twice as often dysphagia.  They also had lower salivary flow rates than 
did acute LT recipients.  These differences may have been due to the differing etiology of 
their liver disease and also due to immunosuppressive and other xerogenic medications 
(Study IV).   
 
5. Compared with those among population controls, oral mucosal lesions in chronic LT 
recipients were 3-fold-, and precancerous lesions twice as common.  The most common type 
of oral lesion was drug-induced gingival overgrowth; simultaneous use of cyclosporine-A 
and calcium-channel blockers increased its prevalence.  Furthermore, use of steroids led to 
increased risk for Candida.  Frequent oral mucosal lesions may be explained not only by 
immunosuppression but also by the high number of other medications used by LT recipients.  
Since these lesions may offer a risk of becoming malignant, regular oral examinations are 
indicated (Study V).  
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